



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2509136 C 2013/10/29

(11)(21) **2 509 136**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2004/01/21
(87) Date publication PCT/PCT Publication Date: 2004/08/12
(45) Date de délivrance/Issue Date: 2013/10/29
(85) Entrée phase nationale/National Entry: 2005/06/07
(86) N° demande PCT/PCT Application No.: US 2004/000019
(87) N° publication PCT/PCT Publication No.: 2004/067568
(30) Priorité/Priority: 2003/01/24 (US60/442,798)

(51) Cl.Int./Int.Cl. *C12N 15/13* (2006.01),
A61K 39/395 (2006.01), *A61P 19/02* (2006.01),
A61P 25/00 (2006.01), *A61P 37/00* (2006.01),
C07K 16/24 (2006.01)
(72) Inventeurs/Inventors:
DICKINSON, CRAIG DUANE, US;
VASSEROT, ALAIN PHILIPPE, US;
WATKINS, JEFFRY DEAN, US;
LU, JIRONG, US
(73) Propriétaire/Owner:
APPLIED MOLECULAR EVOLUTION, INC., US
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : ANTAGONISTES DE L'IL-1 BETA HUMAINE
(54) Title: HUMAN IL-1 BETA ANTAGONISTS

(57) **Abrégé/Abstract:**

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low k_{off} values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 August 2004 (12.08.2004)

PCT

(10) International Publication Number
WO 2004/067568 A3

(51) International Patent Classification⁷: **C07K 16/24**,
C12N 15/13, 15/85, 5/10, A61K 39/395, A61P 19/02,
37/00, 25/00

(21) International Application Number:
PCT/US2004/000019

(22) International Filing Date: 21 January 2004 (21.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/442,798 24 January 2003 (24.01.2003) US

(71) Applicant (for all designated States except US): **AP-
PLIED MOLECULAR EVOLUTION, INC** [US/US];
3520 Dunhill Street, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DICKINSON,**
Craig, Duane [US/US]; 15165 Susita Street, San Diego,
CA 92129 (US). **VASSEROT, Alain, Philippe** [CH/US];
6421 La Paloma Street, Carlsbad, CA 92009 (US).
WATKINS, Jeffry, Dean [US/US]; 3442 Fortuna Ranch
Road, Encinitas, CA 92024 (US). **LU, Jirong** [US/US];
6332 Vancouver Court, Indianapolis, IN 46236 (US).

(74) Agent: **APELGREN, Lynn, D.**; ELI LILLY AND COM-
PANY, P.O. Box 6288, indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG)
- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG)
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,

[Continued on next page]

(54) Title: HUMAN IL-1 BETA ANTAGONISTS

(57) Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low k_{off} values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.

WO 2004/067568 A3

WO 2004/067568 A3



*IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)*

(88) Date of publication of the international search report:
7 October 2004

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

HUMAN IL-1 BETA ANTAGONISTS

BACKGROUND OF THE INVENTION

Interleukin-1 β (IL-1 β) is a proinflammatory cytokine. IL-1 β over-production has
5 been implicated in the pathogenesis of a variety of diseases such as rheumatoid arthritis
and osteoarthritis. IL-1 β has been shown to increase cell migration into the inflamed
synovium of joints by the up-regulation of adhesion molecules, the stimulation of the
production of prostaglandins and metalloproteinase, the inhibition of collagen and
proteoglycan synthesis, and the stimulation of osteoclastic bone resorption. Because of
10 these properties, IL-1 β is one of the primary mediators of bone and cartilage destruction
in arthritis. Thus, agents that reduce the activity of IL-1 β represent possible treatments
for diseases such as arthritis.

There are three members of the IL-1 gene family: IL-1 α , IL-1 β , and IL-1 receptor
antagonist (IL-1ra). IL-1 α and IL-1 β are agonists of the IL-1 receptor whereas the IL-1ra
15 is a specific receptor antagonist and thus, an endogenous competitive inhibitor of IL-1.
Administration of recombinant IL-1ra to patients in clinical trials provided significant
clinical improvements in patients with severe rheumatoid arthritis compared to placebo.
Furthermore, administration of IL-1ra reduced the rate of progressive joint damage.
However, the poor pharmacokinetic properties and the large dose that must be
20 administered make recombinant IL-1ra a less than ideal therapeutic agent.

A high affinity neutralizing antibody to IL-1 β would make a superior therapeutic
agent. The typical long elimination half-lives of antibodies coupled with high affinity
binding result in a therapeutic with a reduced dose and frequency compared with
recombinant IL-1ra. Although numerous IL-1 β antibodies have been described, it has
25 been exceedingly difficult to identify monoclonal antibodies having high affinity, high
specificity, and potent neutralizing activity.

The present invention encompasses humanized IL-1 β antibodies derived from a
unique murine antibody directed against human IL-1 β , Mu007 (see PCT/US02/21281).
These antibodies are high affinity antibodies with improved stability that have potent IL-
30 1 β neutralizing activity and are highly specific for IL-1 β .

- 2 -

SUMMARY OF THE INVENTION

This invention encompasses an isolated antibody, or an antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody is comprised of a light chain and a heavy chain and wherein said light chain is further comprised of a light chain CDR1 selected from the group consisting of SEQ ID NOS: 1, 12, 22, 29, 31, 33, 37, or 39; a light chain CDR2; and, a light chain CDR3 selected from the group consisting of SEQ ID NOS: 3, 7, 13, 15, 17, 20, 25, 34, or 41; and, said heavy chain is further comprised of a heavy chain CDR1 selected from the group consisting of SEQ ID NOS: 4 or 10; a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOS: 5, 8, 16, 18, 21, 23, or 28; and a heavy chain CDR3 selected from the group consisting of SEQ ID NOS: 6, 9, 11, 14, 19, 24, 26, 27, 30, 32, 35, 36, 38, 40, or 42; provided that said antibody does not consist of a light chain CDR1 of SEQ ID NO:1, a light chain CDR2 of SEQ ID NO:2, a light chain CDR3 of SEQ ID NO:3, a heavy chain CDR1 of SEQ ID NO:4, a heavy chain CDR2 of SEQ ID NO:5, and a heavy chain CDR3 of SEQ ID NO:6.

The invention includes antibodies that bind mature human IL-1 β with a K_d of 1×10^{-11} M or less and dissociate from mature human IL-1 β with a k_{off} rate constant of $1 \times 10^{-3} s^{-1}$ or less as determined by surface plasmon resonance (HBS-EP buffer, pH 7.4 at 25°C), and neutralize human IL-1 β activity in a standard T1165.17 proliferation assay.

The invention further provides antibodies, preferably humanized antibodies, or antigen-binding portions thereof, in which deamidation is eliminated at position 55 of the heavy chain complementarity determining region 2 (HCDR2; SEQ ID NO: 44) resulting in improved stability.

The invention includes humanized antibodies comprising a light chain variable framework of human origin and three CDRs and a heavy chain variable framework of human origin and three CDRs having amino acid sequences encoded by polynucleotide sequences that correspond to SEQ ID NOS: 55-64.

Additionally, the invention includes humanized antibodies comprising a light chain variable framework of human origin and three CDRs and a heavy chain variable framework of human origin and three CDRs having amino acid sequences that correspond to SEQ ID NOS: 48-54, and 68.

- 3 -

The invention includes isolated nucleic acids comprising polynucleotides that encode the antibodies described and claimed herein. The invention also encompasses host cells transfected with these polynucleotides that express the antibodies described and claimed herein.

5 The invention encompasses methods of treating rheumatoid arthritis and osteoarthritis which comprise administering to a subject an effective amount of an antibody described and claimed herein as well as a method of inhibiting the destruction of cartilage that occurs in subjects that are prone to or have arthritis.

10 The invention further encompasses methods of treating neuroinflammation associated with stroke and ischemic, excitotoxic, and traumatic head injury which comprise administering to a subject an effective amount of an antibody described and claimed herein.

15 The invention still further encompasses the use of an antibody for the manufacture of a medicament to treat a subject with rheumatoid arthritis, osteoarthritis, or to inhibit cartilage destruction in a subject in need thereof.

 Finally, the invention further encompasses the use of an antibody for the manufacture of a medicament to treat a subject with neuroinflammation associated with stroke and ischemic, excitotoxic, and traumatic head injury.

20 **DETAILED DESCRIPTION OF THE INVENTION**

 This invention encompasses isolated human antibodies, or antigen-binding portions thereof, comprised substantially of the complementarity determining regions (CDRs) of the Mu007 antibody (SEQ ID NOS: 1-6) but wherein the polypeptide structures contain one or more amino acid differences in one or more of the CDRs thereof. The framework and other portions of these antibodies may originate from a human germ line. The humanized versions of Mu007 bind to human IL-1 β with high affinity, a slow off rate and have a high neutralizing capacity. Various aspects of the invention relate to antibodies and antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments. Methods of using the antibodies of the invention to inhibit human IL-1 β activity are also encompassed by the invention.

25

30

- 4 -

In order that the present invention may be more readily understood, certain terms are first defined.

The term "antibody", as used herein, is intended to refer to immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

Light chains are classified as kappa and lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 3 or more amino acids.

IgG antibodies are the most abundant immunoglobulin in serum. IgG also has the longest half-life in serum of any immunoglobulin. Unlike other immunoglobulins, IgG is efficiently recirculated following binding to FcRn. There are four IgG subclasses G1, G2, G3, and G4, each of which have different effector functions. G1, G2, and G3 can bind C1q and fix complement while G4 cannot. Even though G3 is able to bind C1q more efficiently than G1, G1 is more effective at mediating complement-directed cell lysis. G2 fixes complement very inefficiently. The C1q binding site in IgG is located at the carboxy terminal region of the CH2 domain.

All IgG subclasses are capable of binding to Fc receptors (CD16, CD32, CD64) with G1 and G3 being more effective than G2 and G4. The Fc receptor binding region of IgG is formed by residues located in both the hinge and the carboxy terminal regions of the CH2 domain.

- 5 -

The term "antigen-binding portion" of an antibody (or simply "antibody portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., human IL-1 β). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.

5 Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH I domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH

10 domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341: 544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in

15 which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242: 423-426: and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed.

20 Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, R. J., et al.

25 (1994) Structure 2: 1121-1123).

Still further, an antibody or antigen-binding portion thereof may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a

30 tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6: 93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et

- 6 -

al. (1994) Mol. Immunol. 31: 1047-1058). Antibody portions, such as Fab and F(ab')₂ fragments, can be prepared from whole antibodies using conventional techniques, such as papain or pepsin digestion, respectively, of whole antibodies. Moreover, antibodies, antibody portions and immunoadhesion molecules can be obtained using standard
5 recombinant DNA techniques, as described herein.

The term "humanized antibody" means an antibody that is composed partially or fully of amino acid sequences derived from a human antibody germline or a rearranged sequence and made by altering the sequence of an antibody having non-human complementarity determining regions (CDR). The framework regions of the variable
10 regions are substituted by corresponding human framework regions. As discussed herein, antibody in the context of humanized antibody is not limited to a full-length antibody and can include fragments and single chain forms.

The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means,
15 such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucleic Acids Res. 20: 6287-6295) or antibodies prepared, expressed, created or isolated by any other means that
20 involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the
25 amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire *in vivo*.

An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an
30 isolated antibody that specifically binds human IL-1 β is substantially free of antibodies that specifically bind antigens other than human IL-1 β). An isolated antibody that specifically binds human IL-1 β may, however, have cross-reactivity to other antigens,

- 7 -

such as IL-1 β molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

A "neutralizing antibody", as used herein (or an "antibody that neutralizes human IL-1 β activity"), is intended to refer to an antibody whose binding to human IL-1 β results in inhibition of the biological activity of human IL-1 β . Measuring one or more indicators of IL-1 β biological activity as determined using either the T1165.17 cell bioassay or the human IL-1 β neutralization protocol described herein can assess this inhibition of the biological activity of human IL-1 β .

Antibodies that "specifically bind" mature human IL-1 β include antibodies as defined above that bind the mature form of human IL-1 β known in the art and do not bind mature human IL-1 α . An antibody that specifically binds mature human IL-1 β may show some cross-reactivity with mature IL-1 β from other species.

The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Example 1 and Jonsson, U., et al. (1993) Ann. Biol. Clin. 51: 19-26; Jonsson, U., et al. (1991) Biotechniques 11: 620-627; Johnson, B., et al. (1995) J. Mol. Recognit. 8: 125-131; and Johnson, B., et al. (1991) Anal. Biochem. 198: 268-277.

The term " k_{on} ", as used herein is intended to refer to the association or on rate constant, or specific reaction rate, of the forward, or complex-forming, reaction, measured in units: $M^{-1}sec^{-1}$.

The term " k_{off} ", as used herein, is intended to refer to the dissociation or off rate constant, or specific reaction rate, for dissociation of an antibody from the antibody/antigen complex, measured in units: sec^{-1} .

The term " K_d ", as used herein, is intended to refer to the dissociation constant of a particular antibody-antigen interaction. It is calculated by the formula:

$$k_{off}/k_{on} = K_d$$

The antibodies of the present invention are high potency antibodies, generally exhibiting low k_{off} values. For purposes of the present disclosure, the term "high

- 8 -

potency" refers to a potency reflected by a low IC_{50} (or effective concentration showing a reduction of 50% in ^3H thymidine incorporation in the below described bioassay). The antibodies according to the present invention may be neutralizing (causing destruction of the target species, such as a IL-1 β). An antibody not neutralizing for one use may be neutralizing for a different use.

The term "nucleic acid molecule", as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term "isolated nucleic acid molecule", as used herein in reference to nucleic acids encoding antibodies or antibody portions (e.g., VH, VL, CDR3) that bind human IL-1 β is intended to refer to a nucleic acid molecule in which the nucleotide sequences encoding the antibody or antibody portion are free of other nucleotide sequences encoding antibodies or antibody portions that bind antigens other than human IL-1 β , which other sequences may naturally flank the nucleic acid in human genomic DNA. Thus, for example, an isolated nucleic acid of the invention encoding a VH region of an anti-human IL-1 β antibody contains no other sequences encoding other VH regions that bind antigens other than human IL-1 β .

The term "deamidated or deamidation" refers to the degradation of Asn or Gln residues in a protein/peptide (Robinson, *et al.* (2001) *Proc. Natl. Acad. Sci. USA* 12409-12413). For example, the intramolecular pathway for asparagine deamidation is via intermediate succinimide formation, resulting in a mixture of aspartyl and isoaspartyl residues (Harris, *et al.* (2001) *J. of Chromatography* 752: 233-245). Deamidation may lead to a reduction of stability and/or the reduction or loss of activity of the protein. Deamidation can occur *ex vivo* during the preparation of the formulated therapeutic, negatively impacting the manufacturing and storage of the pharmaceutical agent. Moreover, the deamidation can occur *in vivo* affecting the antibody's efficacy and duration of action.

The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.

– 9 –

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced.

It has been found that a deamidation site in the CDR2 region of the Mu007 heavy
5 chain influences the biological properties of humanized antibodies that contain this CDR2
region (see US provisional patent application 60/361423). Analogs of humanized
antibodies that slow down or eliminate deamidation result in an antibody with improved
stability. Thus, the invention includes antibodies in which deamidation is eliminated at
position Asn55 of the heavy chain complementarity determining region 2 (HCDR2) by
10 site specific changes.

The preferred antibodies or antigen-binding portions thereof of the present
invention generally exhibit improved affinity (low K_d values) and have binding
specificity and potency similar to that observed for Mu007 and in which deamidation is
eliminated at position Asn55 of HCDR2. The properties that define the antibodies of the
15 present invention reside primarily in the variable regions of the antibody, more
specifically the CDR regions of the antibody.

The primary impetus for humanizing antibodies from another species is to
reduce the possibility that the antibody causes an immune response when injected
into a human patient as a therapeutic. The more human sequences that are
20 employed in a humanized antibody, the lower the risk of immunogenicity. In
addition, the injected humanized antibodies generally have a longer half-life in
the circulation than injected non-human antibodies. Furthermore, if effector
function is desired, because the effector portion is human, it may interact better
with the other parts of the human immune system. Changes can be made to the
25 sequences described herein as preferable heavy and light chain regions without
significantly affecting the biological properties of the antibody. This is
especially true for the antibody constant regions and parts of the variable regions
that do not influence the ability of the CDRs to bind to IL-1 β .

Furthermore, as discussed herein, human framework variable regions and
30 variants thereof may be used in the present invention. However, regardless of the
framework chosen, if reducing the risk of immunogenicity is a focus, the number
of changes relative to the human framework chosen should be minimized.

- 10 -

The heavy and light chain variable region framework residues can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies. Preferred human framework sequences for the heavy chain variable region of the humanized antibodies of the present invention include the VH segment DP-5 (Tomlinson, *et al.* (1992) *J. Mol. Biol.* 227: 776-798) and the J segment JH4, JH1 or JH5 (Ravetch, *et al.* (1981) *Cell* 27: 583-591). The Vk segment L1 (Cox, *et al.* (1994) *Eur. J. Immunol.* 24: 827-836) and the J segment Jk4 (Hieter, *et al.* (1982) *J. Biol. Chem.* 10: 1516-1522) are preferred sequences to provide the framework for the humanized light chain variable region.

Preferred human heavy chain constant region polynucleotide sequences of the humanized antibodies of the present invention include the IgG1 constant region or the IgG4 constant region:

15 tccaccaagggcccatcggtcttcccgtagcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtaaggactacttccccg
aaccggtgacggtgtcgtggaactcaggcgcctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg
gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaa
tcttgtagaaaaactcacacatgccaccgtgccagcacctgaactcttggggggacgctagcttcttcccccaaaacccaaggacacctcatg
atctcccgacccctgaggtcacatgcgtggtggtggacgtgagccacgaagacctgaggtcaagtcaactggtacgtggacggcgtggaggtgcata
atgccaagacaaagccgaggagcagtagacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggag
20 tacaagtgaaggttccaacaaagccctcccagccccatcgagaaaacctctccaaagccaaagggcagccccgagaaccacaggtgtacacctg
ccccatccccgggacgagctgaccaagaaccaggtcagcctgacctgctgcaaaaggcttctatcccagcgcacatcgccgtggagtgaggagcaat
gggcagccggagaacaactacaagaccacgcccccgctgctggactccgacggctccttcttctctatagcaagctcaccgtggacaagagcaggtgg
cagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga
IgG1 [SEQ ID NO: 65]
25 ctagcgcctgtcctcaggagcacctccgagagcacagccgcctgggctgcctggtaaggactacttccccgaaccggtgacggtgtcgtggaactca
ggcgcctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtagcgtgccctccagcagcttggg
cacgaagacctacacctgcaacgtagatcacaagcccagcaacaccaaggtggacaagagagttgagtcacaaataggtcccccatgccacctgccc
agcacctgagttctggggggaccatcagttcttctgttcccccaaaacccaaggacactctcatgtatctccggacccctgaggtcacgtgcgtggtggt
30 ggacgtgagccaggaagacccccaggtccagttcaactggtacgtggatggcgtggaggtgcataatgccaagacaaagccgaggagcaggttca
acagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaacggcaaggagtacaagtgaaggcttccaacaaaggcctccgctc
ctccatcgagaaaacctctccaaagccaaagggcagccccgagagccacaggtgtacacctgcccccatcccaggaggagatgaccaagaaccagg
tcagcctgacctgctgcaaaaggcttctatcccagcgcacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaagaccacgcctc
ccgtgctggactccgacggctccttcttctctacagcaggctaaccgtggacaagagcaggtggcaggagggaatgtcttctcatgctccgtgatgcatg
35 aggtctgcacaaccactacacagaagagcctctccctgtctctgggtaaat
IgG4 [SEQ ID NO: 66].

The preferred human light chain constant region polynucleotide sequence of the humanized antibodies of the present invention is the kappa chain constant region:

40 cgaactgtggctgcaccatctgtcttcatcttcccgcctctgatgagcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccagag
aggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcccaggagagtgctacagagcaggacagcaaggacagcacctacagcctc
agcagcaccctgacgtgagcaaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcggcgtcacaagag
cttcaacaggggagagtgctaa
[SEQ ID NO: 67]

- 11 -

The preferred antibodies of the present invention contain the IgG1 heavy chain constant region [SEQ ID NO: 65] or the IgG4 heavy chain constant region [SEQ ID NO:66] and the kappa light chain constant region [SEQ ID NO: 67], and are designated
 5 by the clone specified in Table 2 (*i.e.*, W13, W17, *etc.*). The variable region polynucleotide sequences for the antibodies W13, W17, W18, W20, and U43, of the present invention include:

W13-Heavy Chain

10 ggatccactggtcaggtgcagctggcgcgtgaggtgaagaagcctggctcctccgtgaaggtctcctgcaaggcttctggctacacattcgac
 cgctattggatcgagtgggtgcgccaggccctggccaaggcctggagtggatgggcgagattctgcctggcagcggcgacattaactacaatgagaagt
 tcaagggccgcgtcacgattaccgcggacaaatccacgagcacagcctacatggagctgagcagcctgcgctctgaggacacggccgtgtattactgtgc
 gcgcatgtactatgattacgaccagggtttgactactggggccagggcaccctggtcaccgtctcctccgcctccaccaaggggcccatcggtcttcccgt
 agc
 15 [SEQ ID NO: 55]

W13-Light Chain

gacatccagatgaccagctctccatcctccctgtctgcatctgtgggcgaccgcgtcaccatcacttgtaagttcagtcaggacattgatcgcttctgacctg
 gtttcagcagaaaccaggcaaagcccctaagtcctgatctatcgctgaagcgctggatggcgtcccatcccgttcagcggcagtggtcttgga
 20 cagatttcactctcaccatcagcagcctgcagcctgaagattttgcaacttattactgcatccagtatgatgagttccgtacaccttcggcggcgccaccaag
 gtggagatcaaa
 [SEQ ID NO: 60]

W17-Heavy Chain

25 ggatccactggtcaggtgcagctggcgcgtgaggtgaagaagcctggctcctccgtgaaggtctcctgcaaggcttctggctacacattcgac
 cgctattggatcgagtgggtgcgccaggccctggccaaggcctggagtggatgggcgagattctgcctggcagcggcgacattaactacaatgagaagt
 tcaagggccgcgtcacgattaccgcggacaaatccacgagcacagcctacatggagctgagcagcctgcgctctgaggacacggccgtgtattactgtgc
 gcgcatgtactatgattacgaccagggtttgacctgtggggccagggcaccctggtcaccgtctcctccgcctccaccaaggggcccatcggtcttcccgt
 agc
 30 [SEQ ID NO: 56]

W17-Light Chain

gacatccagatgaccagctctccatcctccctgtctgcatctgtgggcgaccgcgtcaccatcacttgtaagttcagtcaggacattgatcgcttctgagctg
 gtttcagcagaaaccaggcaaagcccctaagtcctgatctatcgctgaagcgctggatggcgtcccatcccgttcagcggcagtggtcttgga
 35 cagatttcactctcaccatcagcagcctgcagcctgaagattttgcaacttattactgcttcagtatgatgagttccgtacggtttcggcggcgccaccaag
 tggagatcaaa
 [SEQ ID NO: 61]

W18-Heavy Chain

40 ggatccactggtcaggtgcagctggcgcgtgaggtgaagaagcctggctcctccgtgaaggtctcctgcaaggcttctggctacacattcgac
 cgctattggatcgagtgggtgcgccaggccctggccaaggcctggagtggatgggcgagattctgcctggcagcggcaccattaactacaatgagaagt
 tcaagggccgcgtcacgattaccgcggacaaatccacgagcacagcctacatggagctgagcagcctgcgctctgaggacacggccgtgtattactgtgc
 gcgcatgtactatgattacgaccagggtttgacaactggggccagggcaccctggtcaccgtctcctccgcctccaccaaggggcccatcggtcttcccgt
 agc
 45 [SEQ ID NO: 57]

W18-Light Chain

gacatccagatgaccagctctccatcctccctgtctgcatctgtgggcgaccgcgtcaccatcacttgtaagttcagtcaggacattgatcgcttctgagctg
 gtttcagcagaaaccaggcaaagcccctaagtcctgatctatcgctgaagcgctggatggcgtcccatcccgttcagcggcagtggtcttgga

- 12 -

cagatttcactctcaccatcagcagcctgcagcctgaagattttgcaacttattactgcgttcagtatgatgagttccgtacaccttcggcggcgccaccaagg
tggagatcaaaa

[SEQ ID NO: 62]

5 W20-Heavy Chain

ggatccactgggtcaggtgcagctgggtgcagctctggcgctgaggtgaagaagcctggctcctccgtgaaggtctcctgcaaggcttctggctacacattcgac
cgctattggatcgagtgggtgcgccaggccccctggccaaggcctggagtggatggcgagattctgcctggcagcggcgacattaactacaatgagaagt
tcaagggccgcgtcacgattaccgcggacaaatccacgagcacagcctacatggagctgagcagcctgcgtctgaggacacggccgtgtattactgtgc
gcgcatgtactatgattacgaccagggctttagctactggggccagggcaccctggtcaccgtctcctccgctccaccaagggcccatcggtcttcccgt
10 agc

[SEQ ID NO: 59]

W20-Light Chain

gacatccagatgaccagctctccatcctcctgtctgcatctgtggcgaccgcgtcaccatcacttgtaagttcagtcaggacattgatcgcttctgagctg
15 gtttcagcagaaaccaggcaaagccccctaagtcctgatctatcgcgtaagcgctggatggcgctccatcccgttcagcggcagtggtcttgga
cagatttcactctcaccatcagcagcctgcagcctgaagattttgcaacttattactgcgttcagtatgatgagttccgtacaccttcggcggcgccaccaagg
tggagatcaaaa

[SEQ ID NO: 63]

20 U43-Heavy Chain

ggatccactgggtcaggtgcagctgggtgcagctctggcgctgaggtgaagaagcctggctcctccgtgaaggtctcctgcaaggcttctggctacacattcgac
cgctattggatcgagtgggtgcgccaggccccctggccaaggcctggagtggatggcgagattctgcctggcagcggcgacattaactacaatgagaagt
tcaagggccgcgtcacgattaccgcggacaaatccacgagcacagcctacatggagctgagcagcctgcgtctgaggacacggccgtgtattactgtgc
gcgcatgtactatgattacgaccagggctttagcctgtggggccagggcaccctggtcaccgtctcctccgctccaccaagggcccatcggtcttcccgt
25 agc

[SEQ ID NO: 58]

U43-Light Chain

gacatccagatgaccagctctccatcctcctgtctgcatctgtggcgaccgcgtcaccatcacttgtaaggcgagtcaggacattgatcgcttctgagct
30 ggttcagcagaaaccaggcaaagccccctaagtcctgatctatcgcgtaagcgctggatggcgctccatcccgttcagcggcagtggtcttgga
acagatttcactctcaccatcagcagcctgcagcctgaagattttgcaacttattactgcgttcagtatgatgagttccgtacaccttcggcggcgccaccaag
gtggagatcaaaa

[SEQ ID NO: 64]

35 In another embodiment, the mature amino acid sequences of the
antibodies of the present invention, W13, W17, W18, W20, and U43, include:

W13-Heavy Chain

QVQLVQSGAE VKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGDINY
40 NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGFQDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
45 LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK

[SEQ ID NO: 45]

W13-Light Chain

DIQMTQSPSS LSASVGDRVIT ITCKFSQDID RFLTWVQQKP GKAPKSLIYR VKRLVDGVPS
50 RFGSGSGTD FTLTISSLQP EDFATYYCIQ YDEFPYTFGG GTKVEIKRTV AAPSVFIFPP

- 13 -

SDEQLKSGTA SVVCLLNIFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
[SEQ ID NO: 46]

5 W17-IgG1 Heavy Chain

QVQLVQSGAE VKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGDINY
NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGFDLW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
10 PSVFLFPPKP KDTLMIS RTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
[SEQ ID NO: 47]

15

W17-IgG4 Heavy Chain

QVQLVQSGAEVKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGDINY NEKF
KGRVTITADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGFDLW GQGTLVTVSS ASTKGPSVF
PLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
20 GTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLT VLHQDWLNGKEYKCKVSNK
GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSV MHEALHNHYT QKSLSLSLGK
[SEQ ID NO: 68]

25

W17-Light Chain

DIQMTQSPSS LSASVGDRVITCKFSQDID RFLSWFQQKP GKAPKSLIYR VKRLVDGVPS
RFGSGSGTD FTLTISSLQP EDFATYYCVQ YDEFPYGF GG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNIFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYLSSTLT
30 LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
[SEQ ID NO: 48]

W18-Heavy Chain

QVQLVQSGAE VKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGTINY
35 NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGF DNW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMIS RTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
40 LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
[SEQ ID NO: 49]

W18-Light Chain

DIQMTQSPSS LSASVGDRVITCKFSQDID RFLSWFQQKP GKAPKSLIYR VKRLVDGVPS
45 RFGSGSGTD FTLTISSLQP EDFATYYCVQ YDEFPYTF GG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNIFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGE
[SEQ ID NO: 50]

50

W20-Heavy Chain

QVQLVQSGAE VKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGDINY
NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGF DYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
55 GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG

- 14 -

PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK

5 [SEQ ID NO: 51]

W20-Light Chain

DIQMTQSPSS LSASVGDRVIT ITCKFSQDID RFLSWFQQKP GKAPKSLIYR VKRLVDGVPS
RFGSGSGTD FTLTISSLQP EDFATYYCVQ YDEFPYTFGG GTKVEIKRTV AAPSVFIFPP
10 SDEQLKSGTA SVVCLLNIFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEK

[SEQ ID NO: 52]

U43 Heavy Chain

QVQLVQSGAE VKKPGSSVKV SCKASGYTFD RYWIEWVRQA PGQGLEWMGE ILPGSGDINY
NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARMY YDYDQGFSLW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
20 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK

[SEQ ID NO: 53]

U43-Light chain

DIQMTQSPSS LSASVGDRVIT ITCKASQDID RFLSWFQQKP GKAPKSLIYR
VKRLVDGVPS RFGSGSGTD FTLTISSLQP EDFATYYCVQ YDEFPYTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
30 LSSPVTKSFN RGEK

[SEQ ID NO: 54]

The present invention encompasses antibodies or antigen-binding
portions thereof that make use of one or more of light chain CDR1, CDR2, or
35 CDR3, or heavy chain CDR1, [SEQ ID NOS: 1-4], of antibody Mu007. The
CDRs encompassed by the present invention are the hypervariable regions of the
Mu007 antibody that provide the majority of contact residues for the binding of
the antibody to a specific IL-1 β epitope. Thus, the CDRs described herein can be
used to make full-length antibodies as well as functional fragments and analogs
40 or other proteins which when attached to the CDRs maintain the CDRs in an
active structural conformation such that the binding affinity of the protein
employing the CDRs is specific for mature IL-1 β .

The binding affinity of the Mu007 antibody was determined using surface
plasmon resonance (BIAcoreTM) [see Example 1]. In these experiments the

- 15 -

antibody was captured at low density by either protein A or anti-Fc antibody on a BIAcoreTM chip and ligand was flowed past. Build up of mass at the surface of the chip was measured. This analytical method allows the determination in real time of both on and off rates to obtain affinity (K_d) for binding. The Mu007
5 antibody has a K_d of approximately 6.2 pM (picomolar). Preferred humanized antibodies of the present invention, *i.e.*, W13, W17, W18, W20, and U43, had K_d 's of approximately 2.8 pM, 2.8 pM, 4.2 pM, 2.7 pM, and 4.7 pM respectively (see Example 1, Table 3).

It is also preferred that the antibodies or antigen-binding portions thereof
10 of the present invention bind specifically to IL-1 β and not other IL-1 family members or structurally related proteins within the same species.

It is also preferred that the antibodies or antigen-binding portions thereof of the present invention neutralize the biological activity of IL-1 β . Two different assays were utilized to test the ability of Mu007 and preferred antibodies of the
15 present invention to neutralize IL-1 β activity [see Examples 2 and 3].

A murine cell line, T1165.17, that requires low levels of IL-1 β for proliferation was used in the first assay. Human IL-1 β was present at a constant level in the medium and a dilution series of each antibody was added. Inhibition of proliferation provided a measurement of the antibody's ability to block IL-1 β
20 activation of the IL-1 receptor. Proliferation measurements for different concentrations of antibody resulted in an average IC_{50} value of 20.6 pM for Mu007 and 1.2 pM for W13, 1.8 pM for W17, 2.0 pM for W18, and 4.0 pM for U43 respectively (See Example 2, Table 4).

It is preferred that the antibodies or antigen-binding portions thereof of the present invention have an IC_{50} value that is lower than that of Mu007. " IC_{50} "
25 as referred to herein is the measure of potency of an antibody to inhibit the activity of human IL-1 β . IC_{50} is the concentration of antibody that results in 50% IL-1 β inhibition in a single dose experiment. The IC_{50} can be measured by any assay that detects inhibition of human IL-1 β activity. However, the IC_{50} values
30 obtained may vary depending on the assay used. There may even be some variability between experiments using the same assay. For example, the

- 16 -

condition of the IL-1 β dependent cells discussed herein, has an effect on the IC₅₀ values obtained. Thus, the critical value for the purposes of the present invention is a value relative to that obtained using Mu007 or the preferred antibodies of the present invention in a single experiment.

5 The second assay utilized is an IL-6 neutralization assay. Neither Mu007 nor the preferred antibodies of the present invention cross-react with mouse IL-1 β making it difficult to use a mouse model to test neutralizing activity *in vivo*. However, one consequence of the proinflammatory activity of IL-1 β is the induction of IL-6, another proinflammatory cytokine that mediates some of the
10 non-local effects of IL-1 β . Human IL-1 β is able to bind and stimulate the mouse IL-1 β receptor, leading to an elevation of mouse IL-6. Thus, an antibody with neutralizing activity would block the induction of IL-6 in a mouse given a dose of human IL-1 β . Both Mu007 and the antibodies of the present invention demonstrated potent neutralization of human IL-1 β in the murine model of
15 inflammatory stimulation (See Example 3).

 The present invention also is directed to recombinant DNA encoding antibodies which, when expressed, specifically bind to human IL-1 β . Preferably, the DNA encodes antibodies that, when expressed, comprise one or more of the heavy and light chain CDRs of Mu007 [SEQ ID NOS: 1-6], and one or more of
20 the heavy and light chain CDRs of the present invention [SEQ ID NOS: 7-42]. Exemplary DNA sequences which, on expression, code for the polypeptide chains comprising the heavy chain variable regions of the preferred antibodies of the present invention are represented as SEQ ID NOS: 55-59. Exemplary DNA sequences which, on expression, code for the polypeptide chains comprising the
25 light chain variable regions of the preferred antibodies of the present invention are represented as SEQ ID NOS: 60-64.

 The neutralizing antibodies of the present invention are achieved through generating appropriate antibody gene sequences, *i.e.*, amino acid sequences, by arranging the appropriate nucleotide sequences and expressing these in a suitable cell line. Any
30 desired nucleotide sequences can be produced using the method of codon based mutagenesis, as described, for example, in U.S. Pat. Nos. 5,264,563 and 5,523,388. Such

- 17 -

procedures permit the production of any and all frequencies of amino acid residues at any desired codon positions within an oligonucleotide. This can include completely random substitutions of any of the 20 amino acids at a desired position. Alternatively, this process can be carried out so as to achieve a particular amino acid at a desired location within an amino acid chain, such as the novel CDR sequences according to the invention. In sum, the appropriate nucleotide sequence to express any amino acid sequence desired can be readily achieved and using such procedures the novel CDR sequences of the present invention can be reproduced. This results in the ability to synthesize polypeptides, such as antibodies, with any desired amino acid sequences. For example, it is now possible to determine the amino acid sequences of any desired domains of an antibody of choice and, optionally, to prepare homologous chains with one or more amino acids replaced by other desired amino acids, so as to give a range of substituted analogs.

In applying such methods, it is to be appreciated that due to the degeneracy of the genetic code, such methods as random oligonucleotide synthesis and partial degenerate oligonucleotide synthesis will incorporate redundancies for codons specifying a particular amino acid residue at a particular position, although such methods can be used to provide a master set of all possible amino acid sequences and screen these for optimal function as antibody structures or for other purposes. Such methods are described in Cwirla et al, Proc. Natl. Acad. Sci. 87: 6378-6382 (1990) and Devlin et al., Science 249: 404-406 (1990). Alternatively, such antibody sequences can be synthesized chemically or generated in other ways well known to those skilled in the art.

In accordance with the invention disclosed herein, enhanced high potency antibodies can be generated by combining in a single polypeptide structure one or more novel CDR sequences as disclosed herein, each shown to independently result in enhanced potency or biological activity and reduced deamidation. In this manner, several novel amino acid sequences can be combined into one antibody, in the same or different CDRs, to produce antibodies with desirable levels of biological activity. Such desirable levels will often result from producing antibodies whose k_{off} values are at preferably less than 10^{-3} s^{-1} , more preferably less than $5 \times 10^{-4} \text{ s}^{-1}$, and even more preferably less than $1 \times 10^{-4} \text{ s}^{-1}$. By way of a non-limiting example, 36 such novel CDR sequences [SEQ ID NOS: 7-42] may be employed and the resulting antibodies screened for potency, or biological activity, using either the T1165.17 cell bioassay or the human IL-1 β neutralization

- 18 -

protocol described herein, where the antibody demonstrates high affinity for a particular antigenic structure, such as human IL-1 β . The overall result would thus be an iterative process of combining various single amino acid substitutions and screening the resulting antibodies for antigenic affinity and potency in a step-by-step manner, thereby insuring
5 that potency is increased without sacrifice of a desirably high, or at least minimum value for, affinity. This iterative method can be used to generate double and triple amino acid replacements in a stepwise process so as to narrow the search for antibodies having higher affinity (see WO 01/64751 and US 2002/0098189). Consequently, the amino acids of each CDR region of the Mu007 antibody were systematically substituted and the resulting
10 antibodies were screened for antigenic affinity. It was determined that amino acid substitutions at any position in the light chain CDR2 did not result, in general, in an increase in antibody affinity. Thus, a light chain CDR2 of the present invention is preferably Mu007 light chain CDR2 sequence [SEQ ID NO:2] since amino acid substitutions in this CDR did not result in antibodies of higher affinity.

15 Conversely, it must be appreciated that not all locations within the sequences of the different antibody domains may be equal in that substitutions of any kind in a particular location may be helpful or detrimental. In addition, substitutions of certain kinds of amino acids at certain locations may likewise be a plus or a minus regarding affinity. For example, it may not be necessary to try all possible hydrophobic amino
20 acids at a given position. It may be that any hydrophobic amino acid will do as well. On the other hand, an acidic or basic amino acid at a given location may provide large swings in measured affinity.

As already described, K_d is measured by the ratio of the k_{on} and k_{off} constants. For example, a k_{on} of $3.1 \times 10^7 (M^{-1}s^{-1})$ and a k_{off} of $0.9 \times 10^{-4} (s^{-1})$ would combine to give a K_d of
25 $2.9 \times 10^{-12} M$. Thus, affinity can be improved by increasing the k_{on} or decreasing the k_{off} . Accordingly, a decrease in the k_{off} of antibodies of the present invention will likely result in a more efficacious therapeutic agent.

In accordance with the present invention, increased potency of an existing antibody, regardless of its antigen affinity, is achieved through selective changes to one or
30 more of the amino acids present in one or more of the CDR regions of said antibody whereby said amino acid changes have the effect of producing a decrease in the k_{off} for said antibody, preferably with an increase in antibody affinity. Higher potency can be

- 19 -

achieved with a lower k_{off} value even if the affinity remains the same or is reduced somewhat. Such an antibody is most advantageously produced by synthesis of the required polypeptide chains via synthesis in suitably engineered cells having incorporated therein the appropriate nucleotide sequences coding for the required polypeptide chains
5 containing the altered CDR segments. Also in accordance with the present invention, a novel antibody having a desirable level of potency, or biological activity, can be prepared *de novo* by incorporation of selected amino acids at selected locations within the CDR regions of said antibody polypeptide chains using genetically engineered cells as described herein or wholly through chemical synthesis of the required polypeptide chains
10 with subsequent formation of the necessary disulfide bonds.

In accordance with the foregoing, the antibodies of the present invention are high potency monoclonal antibodies. Such antibodies, however, are monoclonal only in the sense that they may be derived from a clone of a single cell type. However, this is not meant to limit them to a particular origin. Such antibodies may readily be produced in
15 cells that commonly do not produce antibodies, such as CHO, NSO, or COS cells. In addition, such antibodies may be produced in other types of cells, especially mammalian and even plant cells, by genetically engineering such cells to express and assemble the polypeptide light and heavy chains forming the antibody product. In addition, such chains can be chemically synthesized but, since they would be specific for a given
20 antigenic determinant, would still constitute "monoclonal" antibodies within the spirit in which that term is used. Thus, as used herein, the term monoclonal antibody is intended to denote more the specificity and purity of the antibody molecules rather than the mere mechanism used for production of said antibodies.

Also as used herein, the term potency is intended to describe the dependency of
25 the effect of the antibody, when utilized for its intended therapeutic purpose, on the concentration of such antibody. Thus, potency means biological activity with respect to a given antigen. By way of non-limiting example, the potency, or biological activity, or biological effect, is measured for an anti-IL-1 β antibody, by either the T1165.17 cell bioassay or the human IL-1 β neutralization protocol, as described herein. Conversely, the
30 affinity of an antibody for the antigen is simply a mathematical measure of the ratio of k_{on} to k_{off} . In addition, the K_d of the antibodies produced according to the methods of the present invention will typically be in the range of 10^{-12} M or less.

– 20 –

In one embodiment, the antibodies or antigen-binding portions thereof of the present invention will commonly comprise a mammalian, preferably a human, constant region and a variable region, said variable region comprising heavy and light chain framework regions and heavy and light chain CDRs, wherein the heavy and light chain framework regions have sequences characteristic of a mammalian antibody, preferably a human antibody, and wherein the CDR sequences are similar to those of an antibody of some species other than a human, preferably a mouse. The CDR sequences of Mu007 are as shown in Table 1.

10

Table 1		
<u>Basic CDR sequences as provided in</u> <u>SEQ ID NOS: 43 and 44</u>		
CDR	Sequence	SEQ ID NO.
L1	KASQDIDRYLS	1
L2	RVKRLVD	2
L3	LQYDEFPYT	3
H1	GYTFSRYWIE	4
H2	EILPGNGNINYNKFKG	5
H3	IYYDYDQGFTY	6

In keeping with the foregoing, and in order to better describe the sequences disclosed according to the invention with respect to a humanized antibody against human IL-1 β , a basic or starting sequence of light and heavy chain variable regions of Mu007 are shown in the light chain variable region--SEQ ID NO: 43, and the heavy chain variable region--SEQ ID NO: 44. Also in accordance with the invention, specific amino acids different from these starting sequences were generated by recombinant methods starting with prepared nucleotide sequences designed to generate said amino acid sequences when expressed in recombinant cells. The products of said cells are the monoclonal antibodies of the present invention provided that no antibody has the combination of SEQ ID NO:1 for CDR L1, SEQ ID NO:2 for CDR L2, SEQ ID NO:3 for CDR L3, SEQ ID NO:4 for CDR H1, SEQ ID NO:5 for CDR H2, and SEQ ID NO:6 for CDR H3.

– 21 –

In one embodiment of the present invention, potency is increased using a neutralizing antibody Fab fragment against human IL-1 β having a K_d of at least 10^{-11} M, and preferably at least 10^{-12} M by decreasing the k_{off} value to at least $10^{-3}s^{-1}$, preferably at least $5 \times 10^{-4}s^{-1}$, more preferably at least $10^{-4}s^{-1}$. The amino acids present in the CDRs of such Fab fragments are shown in Table 2.

Table 2 indicates the amino acid sequences (all sequences in standard amino acid one letter code) of the CDRs employed in the antibodies of the present invention. In Table 2, the locations of key amino acid substitutions made in the corresponding CDRs of Table 1 (i.e., locations at which CDRs differ in amino acids) are indicated in bold face and underlined. The Fab fragments were initially screened by a standard ELISA. IC_{50} values measured by the T1165.17 cell proliferation assay are indicated as a comparison of the recombinantly produced Fab variants with a wild type control (wt/Fab). The Fab variants and subsequent antibodies of the present invention are referred to by their clone designations from Table 2.

Table 2

Sequences of CDRs tending to induce high potency in antibodies

Clone	CDR	Sequence	SEQ ID NO.	IC_{50} wt/Fab
U2	L1	KASQDIDRYLS	1	3
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTFSRYWIE	4	
	H2	EILPGT <u>G</u> TINYN <u>E</u> KFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>Y</u>	9	
U3	L1	KASQDIDRYLS	1	3
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPGT <u>G</u> TINYN <u>E</u> KFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>L</u>	11	
U4	L1	KASQDIDRYLT	12	2
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPGT <u>G</u> TINYN <u>E</u> KFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>L</u>	11	
U5	L1	KASQDIDRYLT	12	0.5
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>N</u> YT	13	
	H1	GYTFSRYWIE	4	
	H2	EILPGT <u>G</u> TINYN <u>E</u> KFKG	8	

- 22 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
U6	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	3
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>T</u> INYNEKFKG	8	
U7	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	2
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>T</u> INYNEKFKG	8	
U8	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	2
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>T</u> INYNEKFKG	16	
U9	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	2
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>D</u> INYNEKFKG	18	
U10	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>L</u>	19	0.5
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>T</u> G <u>T</u> INYNEKFKG	8	
U11	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	2
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPY <u>L</u>	20	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>T</u> INYNEKFKG	8	
U12	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	5
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPY <u>L</u>	20	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>T</u> INYNEKFKG	8	
U13	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	4
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>N</u> YT	13	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>D</u> INYNEKFKG	21	
U14	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	3
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>N</u> YT	13	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>D</u> INYNEKFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	

- 23 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
U15	L1	KASQDIDRYLT	12	2
	L2	RVKRLVD	2	
	L3	IQYDEFPYT	15	
	H1	GYTFDRYWIE	10	
	H2	EILPGTGTINYNEKFKG	8	
	H3	VYYDYDYGF ~~D~~ Y	9	
U16	L1	KASQDIDRYLT	12	0.5
	L2	RVKRLVD	2	
	L3	IQYDEFNYT	13	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGTINYNEKFKG	16	
	H3	VYYDYDYGF ~~D~~ N	14	
U17	L1	KASQDIDRYLT	12	1
	L2	RVKRLVD	2	
	L3	IQYDEFPYT	15	
	H1	GYTFDRYWIE	10	
	H2	EILPGTGTINYNEKFKG	8	
	H3	VYYDYDYGF ~~D~~ Y	9	
U18	L1	KASQDIDRYLT	12	2
	L2	RVKRLVD	2	
	L3	IQYDEFNYT	13	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGTINYNEKFKG	16	
	H3	VYYDYDYGF ~~D~~ N	14	
U19	L1	KASQDIDRYLT	12	2
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPGTGDINYNEKFKG	18	
	H3	VYYDYDYGF ~~D~~ N	14	
U20	L1	KASQDIDRYLS	1	2
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGDINYNEKFKG	21	
	H3	VYYDYDYGF ~~D~~ Y	9	
U21	L1	KASQDIDRYLT	12	2
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPGTGDINYNEKFKG	18	
	H3	VYYDYDYGF ~~D~~ N	14	
U22	L1	KASQDIDRYLS	1	2
	L2	RVKRLVD	2	
	L3	IQYDEFNYT	13	
	H1	GYTFDRYWIE	10	
	H2	EILPGTGTINYNEKFKG	8	
	H3	VYYDYDYGF ~~D~~ Y	9	
U23	L1	KASQDIDRYLS	1	2
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGDINYNEKFKG	21	
	H3	VYYDYDYGF ~~D~~ Y	9	
U24	L1	KASQDIDRYLS	1	10

- 24 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
U25	L2	RVKRLVD	2	0.5
	L3	<u>I</u> QYDEFPYT	15	
	H1	GYTFSRYWIE	4	
	H2	EILPGT <u>G</u> <u>D</u> INYN E KFKG	18	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>N</u> YT	13	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
U26	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	2
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>S</u> GNINYN E KFKG	23	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>Y</u>	9	
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
U27	H1	GYTF <u>D</u> RYWIE	10	2
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>Y</u>	9	
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYDQGF D <u>N</u>	24	
	L1	KASQDIDRYL <u>T</u>	12	
U28	L2	RVKRLVD	2	2
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYDQGF D <u>N</u>	24	
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
U29	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	1
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
U30	H1	GYTF <u>D</u> RYWIE	10	5
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	KASQDIDRYLS	1	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
U31	L2	RVKRLVD	2	1
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTFSRYWIE	9	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
U32	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	1
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD N	14	
	L1	K <u>F</u> SQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
U33	H1	GYTF <u>D</u> RYWIE	10	1
	H2	EILPG <u>S</u> <u>G</u> <u>D</u> INYN E KFKG	21	

- 25 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
U34	L3	<u>V</u> QYDEF <u>P</u> Y <u>L</u>	25	0.2
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> GNINYNEKFKG	23	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	
	L1	K <u>F</u> SQDIDRYLT	22	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> YT	17	
	H1	GYTF <u>D</u> RYWIE	10	
U35	H2	EILPG <u>S</u> GNINYNEKFKG	23	1
	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>Y</u>	26	
	L1	KASQDIDRYLT	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>L</u>	25	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> GTINYNEKFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>N</u>	27	
U36	L1	KASQDIDRYLT	12	5
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> YT	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>D</u> INYNEKFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>Y</u>	26	
	L1	K <u>F</u> SQDIDRYLT	22	
	L2	RVKRLVD	2	
U37	L3	<u>V</u> QYDEF <u>P</u> YT	17	2
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>S</u> G <u>D</u> INYNEKFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>Y</u>	9	
	L1	KASQDIDRYLT	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTFSRYWIE	4	
U38	H2	EILPG <u>T</u> G <u>D</u> INYNEKFKG	18	1
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	
	L1	K <u>F</u> SQDIDRYLT	22	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>T</u> G <u>D</u> INYNEKFKG	18	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	
U39	L1	K <u>F</u> SQDIDRYLT	22	2
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>P</u> YT	15	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>T</u> G <u>D</u> INYNEKFKG	18	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>N</u>	14	
	L1	K <u>F</u> SQDIDRYLT	22	
	L2	RVKRLVD	2	
U40	L3	<u>I</u> QYDEF <u>P</u> Y <u>L</u>	20	1
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>T</u> G <u>D</u> INYNEKFKG	18	
	H3	<u>V</u> YYDYD <u>Y</u> GFD <u>L</u>	11	
	L1	K <u>F</u> SQDIDRYLT	22	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> YT	17	
	H1	GYTFSRYWIE	4	
U41	H2	EILPG <u>T</u> GNINYNEKFKG	28	1
	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>L</u>	19	
	L1	KASQDIDR <u>F</u> LS	29	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> YT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPG <u>T</u> GNINYNEKFKG	28	
	H3	<u>V</u> YYDYD <u>Y</u> GFT <u>L</u>	19	
U43	L1	KASQDIDR <u>F</u> LS	29	10
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> YT	17	

- 26 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
U44	H1	GYTF <u>D</u> RYWIE	10	5
	H2	EILPG <u>S</u> G <u>D</u> INYN E KFKG	21	
	H3	<u>M</u> YYDYDQGF <u>S</u> L	30	
	L1	KASQDIDR <u>F</u> L <u>T</u>	31	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
V3	H1	GYTF <u>D</u> RYWIE	10	5
	H2	EILPG <u>S</u> G <u>T</u> INYN E KFKG	16	
	H3	<u>M</u> YYDYDQGF <u>T</u> N	32	
	L1	KASQDIDR <u>F</u> L <u>S</u>	33	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
V4	H1	GYTF <u>D</u> RYWIE	10	10
	H2	EILPG <u>S</u> G <u>D</u> INYN E KFKG	21	
	H3	<u>M</u> YYDYDQGF <u>S</u> L	30	
	L1	KASQDIDR <u>F</u> L <u>T</u>	31	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>A</u> YT	34	
V5	H1	GYTF <u>D</u> RYWIE	10	5
	H2	EILPG <u>S</u> G <u>D</u> INYN E KFKG	21	
	H3	<u>M</u> YYDYDQGF <u>D</u> Y	35	
	L1	KASQDIDR <u>F</u> L <u>T</u>	31	
	L2	RVKRLVD	2	
	L3	LQYDEFPYT	3	
V6	H1	GYTF <u>D</u> RYWIE	10	3
	H2	EILPG <u>T</u> G <u>T</u> INYN E KFKG	8	
	H3	<u>M</u> YYDYDQGF <u>D</u> N	36	
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
V7	H1	GYTF <u>D</u> RYWIE	10	2
	H2	EILPG <u>T</u> G <u>T</u> INYN E KFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> G <u>F</u> <u>D</u> N	14	
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
V8	H1	GYTF <u>S</u> RYWIE	4	3
	H2	EILPG <u>T</u> G <u>D</u> INYN E KFKG	18	
	H3	<u>V</u> YYDYD <u>Y</u> G <u>F</u> <u>D</u> N	14	
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEFPYT	15	
W1	H1	GYTF <u>D</u> RYWIE	10	2
	H2	EILPG <u>T</u> G <u>T</u> INYN E KFKG	8	
	H3	<u>V</u> YYDYD <u>Y</u> G <u>F</u> <u>D</u> Y	9	
	L1	KASQDIDRYL <u>T</u>	12	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>N</u> YT	7	
W2	H1	GYTF <u>S</u> RYWIE	4	4
	H2	EILPG <u>S</u> G <u>D</u> INYN E KFKG	21	
	H3	<u>V</u> YYDYD <u>Y</u> G <u>F</u> <u>D</u> N	14	
	L1	<u>K</u> ESQDIDRYL <u>T</u>	22	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEFPYT	17	
	H1	GYTF <u>D</u> RYWIE	10	

- 27 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
W3	H2	EILPGTGDINYNKFKG	18	10
	H3	VYYDYDYGF ~~DN~~	14	
	L1	KASQDIDR ~~FLT~~	31	
	L2	RVKRLVD	2	
	L3	LQYDEFPYT	3	
W4	H1	GYTF ~~DRY~~ WIE	10	10
	H2	EILPGSGDINYNKFKG	21	
	H3	MYDYDYDQGF ~~DY~~	35	
	L1	KASQDIDR ~~FLT~~	31	
	L2	RVKRLVD	2	
W5	L3	LQYDEFPYT	3	10
	H1	GYTF ~~DRY~~ WIE	10	
	H2	EILPGTGTINYNKFKG	8	
	H3	MYDYDYDQGF ~~DY~~	35	
	L1	KFSQDIDR ~~FLT~~	37	
W6	L2	RVKRLVD	2	5
	L3	VQYDEFPYT	17	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGDINYNKFKG	21	
	H3	MYDYDYDQGF ~~SL~~	30	
W8	L1	KFSQDIDR ~~FLT~~	37	5
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
	H1	GYTF ~~DRY~~ WIE	10	
	H2	EILPGTGTINYNKFKG	8	
W9	H3	MYDYDYDQGF ~~TN~~	32	5
	L1	KASQDIDR ~~FLT~~	31	
	L2	RVKRLVD	2	
	L3	IQYDEFPYT	15	
	H1	GYTFSRYWIE	4	
W12	H2	EILPGSGTINYNKFKG	16	10
	H3	MYDYDYDQGF ~~DY~~	35	
	L1	KASQDIDR ~~FLT~~	31	
	L2	RVKRLVD	2	
	L3	VQYDEFPYT	17	
W13	H1	GYTFSRYWIE	4	15
	H2	EILPGSGDINYNKFKG	21	
	H3	MYDYDYDQGF ~~DL~~	38	
	L1	KFSQDIDR ~~FLS~~	39	
	L2	RVKRLVD	2	
W14	L3	VQYDEFPYT	17	10
	H1	GYTF ~~DRY~~ WIE	10	
	H2	EILPGSGNINYNKFKG	23	
	H3	MYDYDYDQGF ~~TL~~	40	
	L1	KFSQDIDR ~~FLT~~	37	
W14	L2	RVKRLVD	2	10
	L3	VQYDEFPYG	41	
	H1	GYTFSRYWIE	4	
	H2	EILPGSGDINYNKFKG	21	
	H3	MYDYDYDQGF ~~DY~~	35	
W14	L1	KFSQDIDR ~~FLS~~	39	10
	L2	RVKRLVD	2	
	L3	VQYDEFPYG	41	
	H1	GYTFSRYWIE	4	
	H2	EILPGTGDINYNKFKG	18	

- 28 -

Clone	CDR	Sequence	SEQ ID NO.	IC ₅₀ wt/Fab
W17	H3	<u>M</u> YYDYDQGFD <u>N</u>	36	20
	L1	K <u>F</u> SQDIDR <u>F</u> LS	39	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>G</u>	41	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>D</u> INYN <u>E</u> KFKG	21	
W18	H3	<u>M</u> YYDYDQGFD <u>L</u>	38	10
	L1	K <u>F</u> SQDIDR <u>F</u> LS	39	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>T</u>	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>T</u> INYN <u>E</u> KFKG	16	
W19	H3	<u>M</u> YYDYDQGFD <u>N</u>	36	10
	L1	K <u>F</u> SQDIDR <u>F</u> LS	39	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>T</u>	17	
	H1	GYTF <u>S</u> RYWIE	4	
	H2	EILPG <u>S</u> G <u>N</u> INYN <u>E</u> KFKG	23	
W20	H3	<u>M</u> YYDYDQGF <u>T</u> Y	42	10
	L1	K <u>F</u> SQDIDR <u>F</u> LS	39	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>T</u>	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>D</u> INYN <u>E</u> KFKG	21	
W21	H3	<u>M</u> YYDYDQGF <u>D</u> Y	35	8
	L1	K <u>F</u> SQDIDR <u>F</u> L <u>T</u>	37	
	L2	RVKRLVD	2	
	L3	<u>I</u> QYDEF <u>P</u> Y <u>T</u>	15	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>S</u> G <u>T</u> INYN <u>E</u> KFKG	16	
W22	H3	<u>M</u> YYDYDQGF <u>D</u> Y	35	5
	L1	K <u>A</u> SQDIDR <u>F</u> L <u>T</u>	31	
	L2	RVKRLVD	2	
	L3	<u>V</u> QYDEF <u>P</u> Y <u>T</u>	17	
	H1	GYTF <u>D</u> RYWIE	10	
	H2	EILPG <u>T</u> G <u>T</u> INYN <u>E</u> KFKG	8	
	H3	<u>M</u> YYDYDQGF <u>D</u> Y	35	

In specific embodiments, the present invention relates to an isolated antibody comprising a K_d of at least 10^{-11} M and most preferably at least 10^{-12} M and wherein the k_{off} is at least about $10^{-3}s^{-1}$, preferably at least about $5 \times 10^{-4}s^{-1}$, and most preferably at least $1 \times 10^{-4}s^{-1}$ (including all combinations thereof).

Preferred antibodies of the present invention that bind to mature human IL-1 β with a K_d of 1×10^{-11} or less, have a k_{off} rate constant of $1 \times 10^{-3}s^{-1}$ or less, neutralize human IL-1 β activity, and in which deamidation is eliminated at position 55 of HCDR2, are selected from the group consisting of SEQ ID NOS: 45-54.

– 29 –

Standard approaches to characterizing and synthesizing the CDR libraries of single mutations were used (see Wu et al, Proc. Natl. Acad. Sci. U.S.A 95: 6037-6042 (1998)). The target CDR was first deleted for each of the libraries prior to annealing the nucleotides. For synthesis of the libraries, the CDRs of a reference antibody (see FIGS. 1&2) were defined as in Table 1. Codon based mutagenesis for oligonucleotide synthesis to yield the CDR sequences of the invention was employed.

Libraries were initially screened by capture lift to identify the highest affinity variants. The capture lift procedure (Watkins, Methods Mol. Biol. 178:187-193, (2002)) is known in the art and is as described in WO/0164751 and US2002/0098189. Subsequently, these clones were further characterized using capture ELISA and by titration on immobilized antigen. Following such screening, the antibodies are then screened for their respective k_{off} values, the positive effects of which are then measured by determination of potency.

The antibodies disclosed herein contain CDRs differing from those of Mu007 in complementarity determining regions L1 (or LCDR1), L3 (or LCDR3), H1 (or HCDR1), H2 (HCDR2) and H3 (or HCDR3).

CDRs of selected Fab fragments are shown in Table 2 (all of which have the framework sequences of FIGs. 3&4) where the reference clone is the clone with heavy and light chain variable region sequences shown in FIGS. 1&2 (SEQ ID NOS: 43 and 44 for the light and heavy chain sequences, respectively).

In accordance with the invention, by combining such amino acid substitutions so that more than one occurred in the same antibody molecule, it was possible to greatly increase the potency of the antibodies disclosed herein.

In general, there is a correlation between low k_{off} and potency of the antibody, with all of the lower k_{off} variants having more than one beneficial CDR, including having up to five CDRs substituted.

The combinations of CDR sequences disclosed in Table 2 can be present in whole tetrameric antibody molecules or in active fragments, such as Fab fragment. The potency data for clones shown in Table 2 are for Fab fragments while the data for clones shown in Table 4 are for whole antibody molecules compared to the reference antibody, Mu007.

The antibodies of the invention can be present in a relatively pure or isolated form as well as in a supernatant drawn from cells grown in wells or on plates. The antibodies

- 30 -

of the invention can thus also be present in the form of a composition comprising the antibody of the invention and wherein said antibody is suspended in a pharmacologically acceptable diluent or excipient. The antibodies of the invention may be present in such a composition at a concentration, or in an amount, sufficient to be of therapeutic or pharmacological value in treating or preventing diseases (for example, preventing rheumatoid arthritis and osteoarthritis). The antibodies may also be present in a composition in a more dilute form.

DNA encoding the antibodies of the present invention will typically further include an expression control polynucleotide sequence operably linked to the antibody coding sequences, including naturally-associated or heterologous promoter regions. Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host cell line, the host cell is propagated under conditions suitable for expressing the nucleotide sequences, and, as desired, for the collection and purification of the light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms.

The nucleic acid sequences of the present invention capable of ultimately expressing the desired antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e.g., V, J, D, and C regions), using any of a variety of well known techniques. Joining appropriate genomic and synthetic sequences is a common method of production, but cDNA sequences may also be utilized.

Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably from immortalized B-cells. Suitable source cells for the polynucleotide sequences and host cells for immunoglobulin expression and secretion can be obtained from a number of sources well-known in the art.

As described herein, in addition to the antibodies specifically described herein, other "substantially homologous" modified antibodies can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled

- 31 -

in the art. For example, the framework regions can vary from the native sequences at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like. Moreover, a variety of different human framework regions may be used singly or in combination as a basis for the humanized immunoglobulins of the present invention. In general, modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis.

Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e.g., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in vectors using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce F(ab')₂ fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker.

As stated previously, the polynucleotides will be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline, neomycin, and dihydrofolate reductase, to permit detection of those cells transformed with the desired DNA sequences.

E. coli is a prokaryotic host useful particularly for cloning the polynucleotides of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any of a number of well-known promoters may be present, such as the lactose promoter system, a tryptophan (*trp*) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and

- 32 -

have ribosome binding site sequences and the like, for initiating and completing transcription and translation.

Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

In addition to microorganisms, plant cells may also be used for expression. Optimal methods of plant transformation vary depending on the type of plant. For example, see WO00/53794.

Mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention. Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, Syrian Hamster Ovary cell lines, HeLa cells, myeloma cell lines, transformed B-cells, human embryonic kidney cell lines, or hybridomas. Preferred cell lines are CHO and myeloma cell lines such as SP2/0 and NS0.

Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, cytomegalovirus and the like. Preferred polyadenylation sites include sequences derived from SV40 and bovine growth hormone.

The vectors containing the polynucleotide sequences of interest (e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts.

Once expressed, the antibodies can be purified according to standard procedures, including ammonium sulfate precipitation, ion exchange, affinity (e.g. Protein A), reverse phase, hydrophobic interaction column chromatography, gel electrophoresis, and the like.

- 33 -

Substantially pure immunoglobulins having at least about 90 to 95% purity are preferred, and 98 to 99% or more purity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically or prophylactically, as directed herein.

5 This invention also relates to a method of treating humans experiencing an IL-1 β mediated inflammatory disorder which comprises administering an effective dose of an IL-1 β antibody to a patient in need thereof. The antibodies of the present invention bind to and prevent IL-1 β from binding an IL-1 β receptor and initiating a signal. Various IL-1 β -mediated disorders include rheumatoid arthritis (RA), osteoarthritis (OA), allergy,
10 septic or endotoxic shock, septicemia, asthma, graft versus host disease, Crohn's disease, and other inflammatory bowel diseases. In addition, IL-1 β mediates host defense responses to local and systemic diseases and injury and to neuroinflammation and cell death in neurodegenerative conditions, such as stroke and ischemic, excitotoxic, and traumatic head injury. IL-1 β has also been implicated in chronic degenerative diseases, in
15 particular, multiple sclerosis, Parkinson's and Alzheimer's diseases. Preferably, the IL-1 β antibodies encompassed by the present invention are used to treat RA and/or OA.

 Patients with RA suffer from chronic swelling and inflammation of the joints and ongoing destruction of cartilage and bone. IL-1 β and TNF- α are the most critical cytokines in the pathogenesis of RA. However, while both IL-1 β and TNF- α mediate
20 inflammation, IL-1 β is the primary mediator of bone and cartilage destruction. Activated monocytes and fibroblasts in the synovial tissue produce IL-1 β which in turn stimulates the production of additional pro-inflammatory cytokines, prostaglandins, and matrix metalloproteases. The synovial lining becomes hypertrophied, invading and eroding bone and cartilage.

25 Disease-modifying antirheumatic drugs (DMARDs) such as hydroxychloroquine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine have been used with modest success in the treatment of RA. Their activity in modifying the course of RA is believed to be due to suppression or modification of inflammatory mediators such as IL-1 β . Methotrexate, for example, at doses of 7.5 to 10 mg per week
30 caused a reduction in IL-1 β plasma concentrations in RA patients. Similar results have been seen with corticosteroids. Thus, the IL-1 β antibodies of the present invention may

- 34 -

be used alone or in combinations with DMARDS which may act to reduce IL-1 β protein levels in plasma.

An effective amount of the IL-1 β antibodies of the present invention is that amount which provides clinical efficacy without intolerable side effects or toxicity.

5 Clinical efficacy for RA patients can be assessed using the American College of Rheumatology Definition of Improvement (ACR20). A patient is considered a responder if the patient shows a 20% improvement in the tender joint count, swollen joint count, and 3 of 5 other components which include patient pain assessment, patient global assessment, physician global assessment, Health Assessment Questionnaire, and serum C-
10 reactive protein. Prevention of structural damage can be assessed by the van der Heijde modification of the Sharp Scoring system for radiographs (erosion count, joint space narrowing).

The IL-1 β antibodies of the present invention can also be used to treat patients suffering from osteoarthritis (OA). OA is the most common disease of human joints and
15 is characterized by articular cartilage loss and osteophyte formation. Clinical features include joint pain, stiffness, enlargement, instability, limitation of motion, and functional impairment. OA has been classified as idiopathic (primary) and secondary forms. Criteria for classification of OA of the knee and hip have been developed by the American College of Rheumatology on the basis of clinical, radiographic, and laboratory
20 parameters.

An effective amount of the IL-1 β antibodies of the present invention is the amount which shows clinical efficacy in OA patients as measured by the improvement in pain and function as well as the prevention of structural damage. Improvements in pain and function can be assessed using the pain and physical function subscales of the WOMAC
25 OA Index. The index probes clinically important patient-relevant symptoms in the areas of pain, stiffness, and physical function. Prevention of structural damage can be assessed by measuring joint space width on radiographs of the knee or hip.

Since elevated levels of IL-1 β have been implicated in human neuro-degenerative conditions such as stroke and brain injury (Rothwell, N. J., *et al.*, TINS 23(12): 618-625,
30 2000), the anti-IL-1 β antibodies encompassed by the present invention can also be used to

- 35 -

treat neuroinflammation associated with stroke and ischemic, excitotoxic, and traumatic head injury.

The antibodies of the present invention are administered using standard administration techniques, preferably peripherally (*i.e.*, not by administration into the
5 central nervous system) by intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration.

The pharmaceutical compositions for administration are designed to be appropriate for the selected mode of administration, and pharmaceutically acceptable excipients such as, buffers, surfactants, preservatives, solubilizing agents, isotonicity
10 agents, stabilizing agents and the like are used as appropriate. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton PA, latest edition, provides a compendium of formulation techniques as are generally known to practitioners.

The concentration of the IL-1 β antibody in formulations may be from as low as
15 about 0.1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, stability, and so forth, in accordance with the particular mode of administration selected. Preferred concentrations of the IL-1 β antibody will generally be in the range of 1 to about 100 mg/mL. Preferably, 10 to about 50 mg/mL.

The formulation may include a buffer. Preferably the buffer is a citrate buffer or a
20 phosphate buffer or a combination thereof. Generally, the pH of the formulation is between about 4 and about 8. Preferably, the pH is between about 5 and about 7.5. The pH of the formulation can be selected to balance antibody stability (chemical and physical) and comfort to the patient when administered. The formulation may also include a salt such as NaCl. In addition, the formulation may include a detergent to
25 prevent aggregation and aid in maintaining stability.

The formulation may be sterile filtered after making the formulation, or otherwise made microbiologically acceptable. A preservative such as m-cresol or phenol, or a mixture thereof may be added to prevent microbial growth and contamination.

A typical composition for intravenous infusion could have a volume as much as
30 250 mL of fluid, such as sterile Ringer's solution, and 1-100 mg per mL, or more in antibody concentration. Therapeutic agents of the invention can be frozen or lyophilized

– 36 –

for storage and reconstituted in a suitable sterile carrier prior to use. Lyophilization and reconstitution can lead to varying degrees of antibody activity loss (*e.g.*, with conventional immunoglobulins, IgM antibodies tend to have greater activity loss than IgG antibodies). Dosages may have to be adjusted to compensate.

5 Although the foregoing methods appear to be the most convenient and most appropriate for administration of proteins such as humanized antibodies, by suitable adaptation, other techniques for administration, such as transdermal administration and oral administration may be employed provided proper formulation is designed. In addition, it may be desirable to employ controlled release formulations using
10 biodegradable films and matrices, or osmotic mini-pumps, or delivery systems based on dextran beads, alginate, or collagen. In summary, formulations are available for administering the antibodies of the invention and may be chosen from a variety of options.

 Typical dosage levels can be optimized using standard clinical techniques and will
15 be dependent on the mode of administration and the condition of the patient. Generally, doses will be in the range of 10 µg/kg/month to 10 mg/kg/month.

 The invention is illustrated by the following examples that are not intended to be limiting in any way.

- 37 -

Example 1

Binding Affinity and Specificity

Affinities and specificities of Mu007 and antibodies of the present invention were determined using BIAcore measurements (Table 3). BIAcore™ is an automated biosensor system that measures molecular interactions. (Karlsson, *et al.* (1991) *J. Immunol. Methods* 145: 229-240). In these experiments antibody was captured to a surface at low density on a BIAcore™ chip. Ethyl-dimethylaminopropyl-carbodiimide (EDC) was used to couple reactive amino groups to protein A to a flow cell of a carboxymethyl (CM5) BIAcore™ sensor chip. Protein A was diluted in sodium acetate buffer, pH 4.5, and immobilized on a flow cell of a CM5 chip using EDC to yield 1000 response units. Unreacted sites were blocked with ethanolamine. A flow rate of 60 µl/min was used. Multiple binding/elution cycles were performed by injection a 10 µl solution of 2 µg/mL of the antibodies of the present invention followed by human IL-1β at decreasing concentrations for each cycle (e.g. 1500, 750, 375, 188, 94, 47, 23.5, 12, and 0 picomolar). Elution was performed with glycine-HCl, pH 1.5. BIAevaluation™ was used to analyze the kinetic data. The protocol utilized for determining the affinity of Mu007 is as described in PCT/US02/21281.

Table 3. Binding properties of anti-IL-1β antibodies to human IL-1β determined by BIAcore (HBS-EP buffer, pH 7.4 at 25 °C)

CLONE	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_d (M)
W17 (IgG1)	3.1e7	0.9e-4	2.8e-12
U43 (IgG1)	4.7e7	2.2e-4	4.7e-12
W13 (IgG1)	6.1e7	1.7e-4	2.8e-12
W18 (IgG1)	4.1e7	1.8e-4	4.2e-12
W20 (IgG1)	3.8e7	1.0e-4	2.7e-12
Mu007	2.6e7	1.6e-4	6.2e-12
W17 (IgG4)	3.2e7	1.0e-4	3.3e-12

Example 2

Antibody potency

A murine cell requiring low levels of IL-1β for proliferation was used to determine the ability of the antibodies of the present invention and Mu007 to neutralize human IL-1β. T1165.17 cells that were no longer in log phase growth were washed 3

– 38 –

times with RPMI 1640 (GibcoBRL Cat. # 22400-089) supplemented with 10% fetal calf serum (GibcoBRL Cat. # 10082-147), 1 mM sodium pyruvate, 50 μ M beta mercaptoethanol, and an antibiotic/antimycotic (GibcoBRL Cat. # 15240-062). Cells were plated at 5,000 cells per well of a 96 well plate. Human IL-1 β was present at a constant level of 0.3 pM and a dilution series of antibody was added. Cells were incubated for 20 hours in a 37°C/5 % CO₂ incubator at which point 1 μ Ci ³H-thymidine was added per well and plates incubated an additional 4 hours in the incubator. Cells were harvested and incorporated radioactivity determined by a scintillation counter. Table 4 illustrates inhibition of IL-1 β stimulated proliferation by Mu007 and the antibodies of the present invention (IgG isotypes as indicated).

Table 4: IC₅₀ Measured in the T1165.17 Cell Proliferation Assay

SAMPLE	IC ₅₀ pM	Fold Increase in Potency
Mu007	20.6 $\pm$ 0.5	1
W17 (IgG1)	1.8 $\pm$ 0.3	11
U43 (IgG1)	4.0 $\pm$ 0.2	5
W18 (IgG1)	2.0 $\pm$ 0.1	10
W13 (IgG1)	1.2 $\pm$ 0.1	17
W20 (IgG1)	1.2 $\pm$ 0.1	17
W17 (IgG4)	1.7 $\pm$ 0.1	12

Example 3

Neutralization of human IL-1 β *in vivo*

Human IL-1 β is able to bind and stimulate the mouse IL-1 β receptor, leading to an elevation of mouse IL-6. Time and dose ranging experiments were undertaken to identify the optimal dose of human IL-1 β and the optimal time for induction of mouse IL-6. These experiments indicated that a 3 μ g/kg dose of human IL-1 β and a time of 2 hours post IL-1 β administration gave maximal levels of IL-6 in mouse serum. The antibodies of the present invention were administered IV to mice at 13, 27, 81, and 270 μ g/kg, one hour prior to an s.c. injection of human IL-1 β . At two hours post IL-1 β administration, mice were sacrificed, and IL-6 levels were determined by ELISA. Isotype matched antibodies were used as negative controls. The antibodies of the present invention

– 39 –

blocked the effects of IL-1 β to stimulate the mouse IL-1 β receptor, leading to an elevation of mouse IL-6, in a dose dependent manner (Table 5).

TABLE 5

Antibody	IL-6 Serum Levels pg/ml	Std Dev.
IL-1 β Ctl. (3 μ g/kg)	462.0	279.1
Human IgG Ctl (270 μ g/kg)	1.0	1.0
IL-1 β Ctl. (3 μ g/kg) + Human IgG Ctl (270 μ g/kg)	592.3	303.0
W13 Ctl. (270 μ g/kg)	4.1	2.4
W17 Ctl. (270 μ g/kg)	3.2	2.9
W18 Ctl. (270 μ g/kg)	5.2	2.4
U43 Ctl. (270 μ g/kg)	1.3	1.0
IL-1 β (3 μ g/kg) + W13 Ctl. (13 μ g/kg)	655.4	78.0
IL-1 β (3 μ g/kg) + W13 Ctl. (27 μ g/kg)	277.4	97.3
IL-1 β (3 μ g/kg) + W13 Ctl. (81 μ g/kg)	129.2	20.2
IL-1 β (3 μ g/kg) + W13 Ctl. (270 μ g/kg)	23.4	5.3
IL-1 β (3 μ g/kg) + W17 Ctl. (13 μ g/kg)	566.8	294.0
IL-1 β (3 μ g/kg) + W17 Ctl. (27 μ g/kg)	410.1	107.5
IL-1 β (3 μ g/kg) + W17 Ctl. (81 μ g/kg)	113.7	42.3
IL-1 β (3 μ g/kg) + W17 Ctl. (270 μ g/kg)	27.5	19.6
IL-1 β (3 μ g/kg) + W18 Ctl. (13 μ g/kg)	398.5	143.2
IL-1 β (3 μ g/kg) + W18 Ctl. (27 μ g/kg)	231.8	32.2
IL-1 β (3 μ g/kg) + W18 Ctl. (81 μ g/kg)	77.9	24.7
IL-1 β (3 μ g/kg) + W18 Ctl. (270 μ g/kg)	18.0	5.9
IL-1 β (3 μ g/kg) + U43 Ctl. (13 μ g/kg)	755.7	299.7
IL-1 β (3 μ g/kg) + U43 Ctl. (27 μ g/kg)	509.3	99.6
IL-1 β (3 μ g/kg) + U43 Ctl. (81 μ g/kg)	186.4	80.8
IL-1 β (3 μ g/kg) + U43 Ctl. (270 μ g/kg)	39.3	17.7

5

Example 4

Antibody Expression

The following protocol applies to the expression of any of the antibodies of the present invention.

10

Expression vectors encoding a leader sequence, and either the constant region for Kappa light chain or Gamma 1 heavy chain were used to clone Fab sequences, resulting

– 40 –

in full antibody genes. The vectors can be used in multiple mammalian cell lines for both transient and stable expression.

The vectors are scaled up to generate the amount of DNA needed to support the transfection. The final DNA remains as a closed circular vector when used in transient
5 transfections, and can be linearized when used in a stable transfection. Small-scale transient transfections should be supported to identify the best ratio of LC:HC. In either transfection the vector encoding the light chain (LC) and the heavy chain (HC) are mixed together prior to being transfected into the cells.

The transient transfection is supported in HEK 293 EBNA cells. The transfection
10 is scaled up and cultured for five to seven days post transfection. The supernatant is harvested, and the antibody is purified using conventional approaches for antibodies.

Stable transfections into CHO (Chinese Hamster Ovary)-DG44 cells can be supported using the vectors outlined. The amount of DNA used can vary from 20µg to 200µg. The cells (10^7) are transfected using a BioRad Gene Pulsar II set at 360 V/950 uF.
15 The cells are recovered for 24-72 hours at 37°C/5% CO₂, and then plated under selection (medium w/o hypoxanthine and thymidine, and with varying levels of methotrexate, MTX, for additional pressure).

Stable transfections into NS0 (mouse myeloma) cells can be supported by moving the genes for the LC and HC into expression vectors encoding a glutamine synthetase
20 gene. The amount of DNA used is 40ug total. The cells (10^7) are transfected using a BioRad Gene Pulsar II machine set at 300V/1000uF. The cells are recovered for 24-72 hours at 37°C/10% CO₂ and then plated under selection (medium w/o glutamine and with methionine sulphoximine, MSX, for additional pressure).

Plating for both types of cell lines is supported in 96-well plates at seed densities
25 specific for the cell line (500c/w CHO-DG44, 2000c/w NS0). When visible colony formation is noted in the wells, the plates can be screened for antibody production using ELISA based methods. The wells containing cells with a positive signal for antibody are expanded into 24-well plates. The lines are cultured and evaluated under expression experiments to identify a candidate cell line with acceptable titer and protein quality. The
30 goal of the cell line generation effort is to identify a clone that can be scaled in serum free culture conditions with acceptable titer, growth characteristic and product quality profile.

40-1

SEQUENCE LISTING

<110> Applied Molecular Evolution, Inc.

<120> Human IL-1 Beta Antagonists

<130> X-15950

<150> 60/442,798

<151> 2003-01-24

<160> 68

<170> PatentIn version 3.2

<210> 1

<211> 11

<212> PRT

<213> Murine

<400> 1

Lys Ala Ser Gln Asp Ile Asp Arg Tyr Leu Ser
1 5 10

<210> 2

<211> 7

<212> PRT

<213> Murine

<400> 2

Arg Val Lys Arg Leu Val Asp
1 5

<210> 3

<211> 9

<212> PRT

<213> Murine

<400> 3

Leu Gln Tyr Asp Glu Phe Pro Tyr Thr
1 5

<210> 4

<211> 10

<212> PRT

<213> Murine

<400> 4

Gly Tyr Thr Phe Ser Arg Tyr Trp Ile Glu
1 5 10

<210> 5

<211> 17

<212> PRT

<213> Murine

<400> 5

Glu Ile Leu Pro Gly Asn Gly Asn Ile Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15

40-2

Gly

<210> 6
 <211> 11
 <212> PRT
 <213> Murine

<400> 6

Ile Tyr Tyr Asp Tyr Asp Gln Gly Phe Thr Tyr
 1 5 10

<210> 7
 <211> 9
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 7

Val Gln Tyr Asp Glu Phe Asn Tyr Thr
 1 5

<210> 8
 <211> 17
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 8

Glu Ile Leu Pro Gly Thr Gly Thr Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 9
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 9

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Asp Tyr
 1 5 10

<210> 10
 <211> 10
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

40-3

<400> 10

Gly Tyr Thr Phe Asp Arg Tyr Trp Ile Glu
1 5 10

<210> 11

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 11

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Asp Leu
1 5 10

<210> 12

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 12

Lys Ala Ser Gln Asp Ile Asp Arg Tyr Leu Thr
1 5 10

<210> 13

<211> 9

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 13

Ile Gln Tyr Asp Glu Phe Asn Tyr Thr
1 5

<210> 14

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 14

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Asp Asn
1 5 10

<210> 15

<211> 9

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

40-4

<223> Synthetic Construct

<400> 15

Ile Gln Tyr Asp Glu Phe Pro Tyr Thr
 1 5

<210> 16

<211> 17

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 16

Glu Ile Leu Pro Gly Ser Gly Thr Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 17

<211> 9

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 17

Val Gln Tyr Asp Glu Phe Pro Tyr Thr
 1 5

<210> 18

<211> 17

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 18

Glu Ile Leu Pro Gly Thr Gly Asp Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 19

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 19

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Thr Leu

1 5 10 40-5

<210> 20
 <211> 9
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 20

Ile Gln Tyr Asp Glu Phe Pro Tyr Leu
 1 5

<210> 21
 <211> 17
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 21

Glu Ile Leu Pro Gly Ser Gly Asp Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 22
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 22

Lys Phe Ser Gln Asp Ile Asp Arg Tyr Leu Thr
 1 5 10

<210> 23
 <211> 17
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 23

Glu Ile Leu Pro Gly Ser Gly Asn Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

<210> 24
 <211> 11

40-6

<212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 24

Val Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Asn
 1 5 10

<210> 25
 <211> 9
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 25

Val Gln Tyr Asp Glu Phe Pro Tyr Leu
 1 5

<210> 26
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 26

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Thr Tyr
 1 5 10

<210> 27
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 27

Val Tyr Tyr Asp Tyr Asp Tyr Gly Phe Thr Asn
 1 5 10

<210> 28
 <211> 17
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 28

Glu Ile Leu Pro Gly Thr Gly Asn Ile Asn Tyr Asn Glu Lys Phe Lys
 1 5 10 15

Gly

40-7

<210> 29
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 29

Lys Ala Ser Gln Asp Ile Asp Arg Phe Leu Ser
1 5 10

<210> 30
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 30

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Ser Leu
1 5 10

<210> 31
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 31

Lys Ala Ser Gln Asp Ile Asp Arg Phe Leu Thr
1 5 10

<210> 32
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 32

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Thr Asn
1 5 10

<210> 33
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 33

Lys Ala Ser Gln Asp Ile Asp Arg Phe Leu Ser 40-8
1 5 10

<210> 34
<211> 9
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 34

Val Gln Tyr Asp Glu Phe Ala Tyr Thr
1 5

<210> 35
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 35

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Tyr
1 5 10

<210> 36
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 36

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Asn
1 5 10

<210> 37
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 37

Lys Phe Ser Gln Asp Ile Asp Arg Phe Leu Thr
1 5 10

<210> 38
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 38

40-9

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Leu
 1 5 10

<210> 39
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 39

Lys Phe Ser Gln Asp Ile Asp Arg Phe Leu Ser
 1 5 10

<210> 40
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 40

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Thr Leu
 1 5 10

<210> 41
 <211> 9
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 41

Val Gln Tyr Asp Glu Phe Pro Tyr Gly
 1 5

<210> 42
 <211> 11
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 42

Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Thr Tyr
 1 5 10

<210> 43
 <211> 387
 <212> DNA
 <213> Murine

<400> 43

atggacatga ggaccctgc tcagtttctt ggaatctttt tcttctgggt tccaggtatc

60

40-10

agatgtgaca tcaagatgac ccagtctcca tcttccatgt atgcatctct aggagagaga 120
 gtcactatca cttgcaaggc gagtcaggac attgataggt atttaagttg gttccagcag 180
 aaaccaggga aatctcctaa gaccctgac tatcgtgtaa agagattggt agatggggtc 240
 ccatcaaggt tcagtggcag cgcattctgg caagattatt ctctcaccat cagcagcctg 300
 cagtatgaag atatgggaat ttattattgt ctacagtatg atgagtttcc gtacacgttc 360
 ggagggggga ccaagctgga aataaaa 387

<210> 44
 <211> 417
 <212> DNA
 <213> Murine

<400> 44
 atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcagggtgt ccactcccag 60
 gttcagctgc agcagtctgg agctgagctg atgaagcctg gggcctcagt gaagatatcc 120
 tgcaaggcta ctggctacac attcagtagg tattggatag agtggataaa gcagaggcct 180
 ggacatggcc ttgagtggat tggagagatt ttacctggaa atggaaatat taactacaat 240
 gagaagttca agggcaaggc cacaatctct gcagattctt cctccgaaac agcctacatg 300
 caactcagca gcctgtcctc tgaggactct gccgtctatt attgttcaac aatctactat 360
 gattacgacc aggggtttac ttactggggc caagggactc tggtcactgt ttctgca 417

<210> 45
 <211> 450
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 45

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asp Arg Tyr
 20 25 30

Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Glu Ile Leu Pro Gly Ser Gly Asp Ile Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Tyr Trp Gly Gln

										40-11					
			100					105					110		
Gly	Thr	Leu 115	Val	Thr	Val	Ser	Ser 120	Ala	Ser	Thr	Lys	Gly 125	Pro	Ser	Val
Phe	Pro 130	Leu	Ala	Pro	Ser	Ser 135	Lys	Ser	Thr	Ser	Gly 140	Gly	Thr	Ala	Ala
Leu 145	Gly	Cys	Leu	Val	Lys 150	Asp	Tyr	Phe	Pro	Glu 155	Pro	Val	Thr	Val	Ser 160
Trp	Asn	Ser	Gly	Ala 165	Leu	Thr	Ser	Gly	Val 170	His	Thr	Phe	Pro	Ala 175	Val
Leu	Gln	Ser	Ser 180	Gly	Leu	Tyr	Ser	Leu 185	Ser	Ser	Val	Val	Thr 190	Val	Pro
Ser	Ser	Ser 195	Leu	Gly	Thr	Gln	Thr 200	Tyr	Ile	Cys	Asn	Val 205	Asn	His	Lys
Pro	Ser 210	Asn	Thr	Lys	Val	Asp 215	Lys	Lys	Val	Glu	Pro 220	Lys	Ser	Cys	Asp
Lys 225	Thr	His	Thr	Cys	Pro 230	Pro	Cys	Pro	Ala	Pro 235	Glu	Leu	Leu	Gly	Gly 240
Pro	Ser	Val	Phe	Leu 245	Phe	Pro	Pro	Lys	Pro 250	Lys	Asp	Thr	Leu	Met 255	Ile
Ser	Arg	Thr	Pro 260	Glu	Val	Thr	Cys	Val 265	Val	Val	Asp	Val	Ser 270	His	Glu
Asp	Pro	Glu 275	Val	Lys	Phe	Asn	Trp 280	Tyr	Val	Asp	Gly	Val 285	Glu	Val	His
Asn	Ala 290	Lys	Thr	Lys	Pro	Arg 295	Glu	Glu	Gln	Tyr	Asn 300	Ser	Thr	Tyr	Arg
Val 305	Val	Ser	Val	Leu	Thr 310	Val	Leu	His	Gln	Asp 315	Trp	Leu	Asn	Gly	Lys 320
Glu	Tyr	Lys	Cys	Lys 325	Val	Ser	Asn	Lys	Ala 330	Leu	Pro	Ala	Pro	Ile 335	Glu
Lys	Thr	Ile	Ser 340	Lys	Ala	Lys	Gly	Gln 345	Pro	Arg	Glu	Pro	Gln 350	Val	Tyr
Thr	Leu	Pro 355	Pro	Ser	Arg	Asp	Glu 360	Leu	Thr	Lys	Asn	Gln 365	Val	Ser	Leu
Thr	Cys 370	Leu	Val	Lys	Gly	Phe 375	Tyr	Pro	Ser	Asp	Ile 380	Ala	Val	Glu	Trp

40-12

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Lys
 450

<210> 46
 <211> 214
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 46

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Phe Ser Gln Asp Ile Asp Arg Phe
 20 25 30

Leu Thr Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile
 35 40 45

Tyr Arg Val Lys Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Ile Gln Tyr Asp Glu Phe Pro Tyr
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145										40-13						160
										155						
Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	
				165					170					175		
Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	
			180					185					190			
Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	
		195					200					205				

Phe Asn Arg Gly Glu Cys
210

<210>	47
<211>	450
<212>	PRT
<213>	ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 47

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asp Arg Tyr
20 25 30

Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Glu Ile Leu Pro Gly Ser Gly Asp Ile Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Leu Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160

Trp Asn Ser Gly Ala₁₆₅ Leu Thr Ser Gly Val₁₇₀ His Thr Phe Pro Ala Val₁₇₅
 40-14
 Leu Gln Ser Ser₁₈₀ Gly Leu Tyr Ser Leu₁₈₅ Ser Ser Val Val Thr Val Pro₁₉₀
 Ser Ser Ser₁₉₅ Leu Gly Thr Gln Thr₂₀₀ Tyr Ile Cys Asn Val₂₀₅ Asn His Lys
 Pro Ser Asn Thr Lys Val Asp₂₁₅ Lys Lys Val Glu Pro₂₂₀ Lys Ser Cys Asp
 Lys Thr His Thr Cys Pro₂₃₀ Pro Cys Pro Ala Pro₂₃₅ Glu Leu Leu Gly Gly₂₄₀
 Pro Ser Val Phe Leu₂₄₅ Phe Pro Pro Lys Pro₂₅₀ Lys Asp Thr Leu Met Ile₂₅₅
 Ser Arg Thr Pro₂₆₀ Glu Val Thr Cys Val₂₆₅ Val Val Asp Val Ser His Glu₂₇₀
 Asp Pro Glu Val₂₇₅ Lys Phe Asn Trp₂₈₀ Tyr Val Asp Gly Val₂₈₅ Glu Val His
 Asn Ala Lys Thr Lys Pro Arg₂₉₅ Glu Glu Gln Tyr Asn₃₀₀ Ser Thr Tyr Arg
 Val Val Ser Val Leu Thr₃₁₀ Val Leu His Gln Asp₃₁₅ Trp Leu Asn Gly Lys₃₂₀
 Glu Tyr Lys Cys Lys₃₂₅ Val Ser Asn Lys Ala₃₃₀ Leu Pro Ala Pro Ile₃₃₅ Glu
 Lys Thr Ile Ser₃₄₀ Lys Ala Lys Gly Gln₃₄₅ Pro Arg Glu Pro Gln Val Tyr₃₅₀
 Thr Leu Pro Pro Ser Arg Asp Glu₃₆₀ Leu Thr Lys Asn Gln Val Ser Leu₃₆₅
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile₃₈₀ Ala Val Glu Trp₃₇₀
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys₃₉₅ Thr Thr Pro Pro Val₄₀₀
 Leu Asp Ser Asp Gly₄₀₅ Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp₄₁₅
 Lys Ser Arg Trp Gln Gln Gly Asn Val₄₂₅ Phe Ser Cys Ser Val Met His₄₃₀
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 40-15 445

Gly Lys
450

<210> 48
<211> 214
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 48

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Phe Ser Gln Asp Ile Asp Arg Phe
20 25 30

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile
35 40 45

Tyr Arg Val Lys Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Asp Glu Phe Pro Tyr
85 90 95

Gly Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

40-16

Phe Asn Arg Gly Glu Cys
210

<210> 49
<211> 450
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Synthetic Construct

<400> 49

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asp Arg Tyr
20 25 30

Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Glu Ile Leu Pro Gly Ser Gly Thr Ile Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp Asn Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220

40-17

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Lys
 450

<210> 50
 <211> 213
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

40-18

<400> 50

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Phe Ser Gln Asp Ile Asp Arg Phe
 20 25 30

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile
 35 40 45

Tyr Arg Val Lys Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Asp Glu Phe Pro Tyr
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu
 210

<210> 51

<211> 450

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Synthetic Construct

<400> 51

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser

1					5					10					15
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Asp	Arg	Tyr
			20					25					30		
Trp	Ile	Glu	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Glu	Ile	Leu	Pro	Gly	Ser	Gly	Asp	Ile	Asn	Tyr	Asn	Glu	Lys	Phe
	50					55					60				
Lys	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Ser	Thr	Ala	Tyr
65					70					75					80
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Met	Tyr	Tyr	Asp	Tyr	Asp	Gln	Gly	Phe	Asp	Tyr	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val
		115					120					125			
Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala
	130					135					140				
Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser
145					150					155					160
Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val
				165					170					175	
Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro
			180					185					190		
Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys
		195					200					205			
Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp
	210					215					220				
Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly
225					230					235					240
Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile
				245					250					255	
Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu
			260					265					270		
Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His
		275					280					285			

40-20

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Lys
 450

<210> 52
 <211> 213
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <223> Synthetic Construct

<400> 52

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Phe Ser Gln Asp Ile Asp Arg Phe
 20 25 30

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile
 35 40 45

Tyr Arg Val Lys Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly

<210>	53
<211>	450
<212>	PRT
<213>	ARTIFICIAL SEQUENCE
<220>	
<223>	Synthetic Construct
<400>	53

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asp Arg Tyr
20 25 30

Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Glu Ile Leu Pro Gly Ser Gly Asp Ile Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Ser Leu Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

<210>	54
<211>	213
<212>	PRT
<213>	ARTIFICIAL SEQUENCE
<220>	
<223>	Synthetic Construct
<400>	54

Asp 1	Ile	Gln	Met	Thr 5	Gln	Ser	Pro	Ser	Ser 10	Leu	Ser	Ala	Ser	Val 15	Gly
Asp	Arg	Val	Thr 20	Ile	Thr	Cys	Lys	Ala 25	Ser	Gln	Asp	Ile	Asp 30	Arg	Phe
Leu	Ser	Trp 35	Phe	Gln	Gln	Lys	Pro 40	Lys	Ala	Pro	Lys	Ser 45	Leu	Ile	Tyr
Arg	Val 50	Lys	Arg	Leu	Val	Asp 55	Gly	Val	Pro	Ser	Arg 60	Phe	Ser	Gly	Ser
Gly 65	Ser	Gly	Thr	Asp	Phe 70	Thr	Leu	Thr	Ile	Ser 75	Ser	Leu	Gln	Pro	Glu 80
Asp	Phe	Ala	Thr	Tyr 85	Tyr	Cys	Val	Gln	Tyr 90	Asp	Glu	Phe	Pro	Tyr 95	Thr
Phe	Gly	Gly	Gly 100	Thr	Lys	Val	Glu	Ile 105	Lys	Arg	Thr	Val	Ala 110	Ala	Pro

40-24

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
 115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
 130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
 145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
 180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 195 200 205

Asn Arg Gly Glu Cys
 210

<210> 55
 <211> 407
 <212> DNA
 <213> HUMAN

<400> 55
 ggatccactg gtcaggtgca gctggtgcag tctggcgctg aggtgaagaa gcctggctcc 60
 tccgtgaagg tctcctgcaa ggcttctggc tacacattcg accgctattg gatcgagtgg 120
 gtgcgccagg cccctggcca aggcctggag tggatgggcg agattctgcc tggcagcggc 180
 gacattaact acaatgagaa gttcaagggc cgcgtcacga ttaccgcgga caaatccacg 240
 agcacagcct acatggagct gagcagcctg cgctctgagg acacggccgt gtattactgt 300
 gcgcgcatgt actatgatta cgaccagggc tttgactact ggggccaggg caccctggtc 360
 accgtctcct ccgcctccac caagggccca tcggtcttcc cgctagc 407

<210> 56
 <211> 407
 <212> DNA
 <213> HUMAN

<400> 56
 ggatccactg gtcaggtgca gctggtgcag tctggcgctg aggtgaagaa gcctggctcc 60
 tccgtgaagg tctcctgcaa ggcttctggc tacacattcg accgctattg gatcgagtgg 120
 gtgcgccagg cccctggcca aggcctggag tggatgggcg agattctgcc tggcagcggc 180
 gacattaact acaatgagaa gttcaagggc cgcgtcacga ttaccgcgga caaatccacg 240
 agcacagcct acatggagct gagcagcctg cgctctgagg acacggccgt gtattactgt 300
 gcgcgcatgt actatgatta cgaccagggc tttgacctgt ggggccaggg caccctggtc 360
 accgtctcct ccgcctccac caagggccca tcggtcttcc cgctagc 407

40-25

<210> 57
 <211> 407
 <212> DNA
 <213> HUMAN

<400> 57
 ggatccactg gtcaggtgca gctggtgcag tctggcgctg aggtgaagaa gcctggctcc 60
 tccgtgaagg tctcctgcaa ggcttctggc tacacattcg accgctattg gatcgagtgg 120
 gtgcgccagg cccctggcca aggcctggag tggatgggcg agattctgcc tggcagcggc 180
 accattaact acaatgagaa gttcaagggc cgcgtcacga ttaccgcgga caaatccacg 240
 agcacagcct acatggagct gagcagcctg cgctctgagg acacggccgt gtattactgt 300
 gcgcgcatgt actatgatta cgaccagggc ttgacaact ggggccaggg caccctggtc 360
 accgtctcct ccgcctccac caagggccca tcggtcttcc cgctagc 407

<210> 58
 <211> 407
 <212> DNA
 <213> HUMAN

<400> 58
 ggatccactg gtcaggtgca gctggtgcag tctggcgctg aggtgaagaa gcctggctcc 60
 tccgtgaagg tctcctgcaa ggcttctggc tacacattcg accgctattg gatcgagtgg 120
 gtgcgccagg cccctggcca aggcctggag tggatgggcg agattctgcc tggcagcggc 180
 gacattaact acaatgagaa gttcaagggc cgcgtcacga ttaccgcgga caaatccacg 240
 agcacagcct acatggagct gagcagcctg cgctctgagg acacggccgt gtattactgt 300
 gcgcgcatgt actatgatta cgaccagggc tttagcctgt ggggccaggg caccctggtc 360
 accgtctcct ccgcctccac caagggccca tcggtcttcc cgctagc 407

<210> 59
 <211> 407
 <212> DNA
 <213> HUMAN

<400> 59
 ggatccactg gtcaggtgca gctggtgcag tctggcgctg aggtgaagaa gcctggctcc 60
 tccgtgaagg tctcctgcaa ggcttctggc tacacattcg accgctattg gatcgagtgg 120
 gtgcgccagg cccctggcca aggcctggag tggatgggcg agattctgcc tggcagcggc 180
 gacattaact acaatgagaa gttcaagggc cgcgtcacga ttaccgcgga caaatccacg 240
 agcacagcct acatggagct gagcagcctg cgctctgagg acacggccgt gtattactgt 300
 gcgcgcatgt actatgatta cgaccagggc ttgactact ggggccaggg caccctggtc 360
 accgtctcct ccgcctccac caagggccca tcggtcttcc cgctagc 407

<210> 60
 <211> 321
 <212> DNA
 <213> HUMAN

40-26

<400> 60
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtgggcga ccgcgtcacc 60
atcacttgta agttcagtca ggacattgat cgcttcctga cctgggtttca gcagaaacca 120
ggcaaagccc ctaagtcctt gatctatcgc gtgaagcgcc tgggtggatgg cgtcccatcc 180
cgcttcagcg gcagtggctc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgcatccag tatgatgagt ttccgtacac cttcggcggc 300
ggcaccaagg tggagatcaa a 321

<210> 61
<211> 321
<212> DNA
<213> HUMAN

<400> 61
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtgggcga ccgcgtcacc 60
atcacttgta agttcagtca ggacattgat cgcttcctga gctgggtttca gcagaaacca 120
ggcaaagccc ctaagtcctt gatctatcgc gtgaagcgcc tgggtggatgg cgtcccatcc 180
cgcttcagcg gcagtggctc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgcgttcag tatgatgagt ttccgtacgg tttcggcggc 300
ggcaccaagg tggagatcaa a 321

<210> 62
<211> 321
<212> DNA
<213> HUMAN

<400> 62
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtgggcga ccgcgtcacc 60
atcacttgta agttcagtca ggacattgat cgcttcctga gctgggtttca gcagaaacca 120
ggcaaagccc ctaagtcctt gatctatcgc gtgaagcgcc tgggtggatgg cgtcccatcc 180
cgcttcagcg gcagtggctc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgcgttcag tatgatgagt ttccgtacac cttcggcggc 300
ggcaccaagg tggagatcaa a 321

<210> 63
<211> 321
<212> DNA
<213> HUMAN

<400> 63
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtgggcga ccgcgtcacc 60
atcacttgta agttcagtca ggacattgat cgcttcctga gctgggtttca gcagaaacca 120
ggcaaagccc ctaagtcctt gatctatcgc gtgaagcgcc tgggtggatgg cgtcccatcc 180
cgcttcagcg gcagtggctc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgcgttcag tatgatgagt ttccgtacac cttcggcggc 300
ggcaccaagg tggagatcaa a 321

40-27

<210> 64
 <211> 321
 <212> DNA
 <213> HUMAN

<400> 64
 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtgggcga ccgcgtcacc 60
 atcacttgta aggcgagtca ggacattgat cgcttcctga gctggtttca gcagaaacca 120
 ggcaaagccc ctaagtccct gatctatcgc gtgaagcgcc tgggtggatgg cgtcccatcc 180
 cgcttcagcg gcagtggctc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgcgttcag tatgatgagt ttccgtacac cttcggcggc 300
 ggcaccaagg tggagatcaa a 321

<210> 65
 <211> 990
 <212> DNA
 <213> HUMAN

<400> 65
 tccaccaagg gcccatcggc cttcccgcga gcaccctcct ccaagagcac ctctgggggc 60
 acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 120
 aactcaggcg ccctgaccag cggcgtgcac accttccccg ctgtcctaca gtcctcagga 180
 ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac 240
 atctgcaacg tgaatcaca gccagcaac accaagggtg acaagaaagt tgagcccaaa 300
 tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg 360
 tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gaccctgag 420
 gtcacatgcg tgggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 480
 gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 540
 acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 600
 tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 660
 gccaaagggc agccccgaga accacagggtg tacaccctgc ccccatcccg ggacgagctg 720
 accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 780
 gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc ccccgctgctg 840
 gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag caggtggcag 900
 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 960
 aagagcctct ccctgtctcc gggtaaata 990

<210> 66
 <211> 952
 <212> DNA
 <213> HUMAN

<400> 66
 cttagcgcct gctccaggag cacctccgag agcacagccg ccctgggctg cctggtcaag 60

40-28

gactacttcc ccgaaccggt gacgggtgtcg tggaactcag gcgccctgac cagcggcgtg 120
 cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc 180
 gtgccctcca gcagcttggg cacgaagacc tacacctgca acgtagatca caagcccagc 240
 aacaccaagg tggacaagag agttgagtcc aaatatgggtc ccccatgccc accctgcca 300
 gcacctgagt tcctgggggg accatcagtc ttctgttcc ccccaaaacc caaggacact 360
 ctcatgatct cccggacccc tgaggtcacg tgcgtggtgg tggacgtgag ccaggaagac 420
 cccgaggtcc agttcaactg gtacgtggat ggcgtggagg tgcataatgc caagacaaag 480
 ccgcgggagg agcagttcaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 540
 caggactggc tgaacggcaa ggagtacaag tgcaaggctc ccaacaaagg cctcccgtcc 600
 tccatcgaga aaaccatctc caaagccaaa gggcagcccc gagagccaca ggtgtacacc 660
 ctgcccccat cccaggagga gatgaccaag aaccaggtca gcctgacctg cctggtcaaa 720
 ggcttctacc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 780
 tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaggcta 840
 accgtggaca agagcaggtg gcaggagggg aatgtcttct catgctccgt gatgcatgag 900
 gctctgcaca accactacac acagaagagc ctctccctgt ctctgggtaa at 952

<210> 67
 <211> 324
 <212> DNA
 <213> HUMAN

<400> 67
 cgaactgtgg ctgcaccatc tgtcttcac tccccgcat ctgatgagca gttgaaatct 60
 ggaactgcct ctgttggtg cctgctgaat aacttctatc ccagagagggc caaagtacag 120
 tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180
 agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240
 aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300
 agcttcaaca ggggagagtg ctaa 324

<210> 68
 <211> 467
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 68

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1 5 10 15

Gly Ser Thr Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
 20 25 30

Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
 35 40 45 40-29
 Phe Asp Arg Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly
 50 55 60
 Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asp Ile Asn Tyr
 65 70 75 80
 Asn Glu Lys Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr
 85 90 95
 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
 100 105 110
 Val Tyr Tyr Cys Ala Arg Met Tyr Tyr Asp Tyr Asp Gln Gly Phe Asp
 115 120 125
 Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 145 150 155 160
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn
 210 215 220
 Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
 225 230 235 240
 Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly
 245 250 255
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 260 265 270
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln
 275 280 285
 Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 290 295 300
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr

- 41 -

CLAIMS

1. An isolated antibody that specifically binds human IL-1 β , wherein said antibody comprises:

- 5 a) a light chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 39;
b) a light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 2;
c) a light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 41;
d) a heavy chain CDR1 consisting of the amino acid sequence of SEQ ID NO:
10;
10 e) a heavy chain CDR2 consisting of the amino acid sequence of SEQ ID NO:
21; and,
f) a heavy chain CDR3 consisting of the amino acid sequence of SEQ ID NO:
38.

15 2. The antibody of claim 1 wherein said antibody comprises a heavy chain variable region encoded by the polynucleotide sequence as shown in SEQ ID NO: 56 and a light chain variable region encoded by the polynucleotide sequence as shown in SEQ ID NO: 61.

20 3. The antibody of claim 1 wherein said antibody comprises a heavy chain wherein the amino acid sequence is given by SEQ ID NO: 47 and a light chain wherein the amino acid sequence is given by SEQ ID NO: 48.

25 4. The antibody of claim 1 wherein said antibody comprises a heavy chain wherein the amino acid sequence is given by SEQ ID NO: 68 and a light chain wherein the amino acid sequence is given by SEQ ID NO: 48.

5. The isolated antibody of any one of claims 1 to 4, wherein said antibody has an IgG isotype.

30

6. The isolated antibody of claim 5, wherein the isotype is heavy chain constant regions IgG1 or IgG4.

- 42 -

7. The isolated antibody of claim 6, wherein the isotype is IgG1 encoded by the polynucleotide as shown in SEQ ID NO: 65.

5 8. The isolated antibody of claim 6, wherein the isotype is IgG4 encoded by the polynucleotide as shown in SEQ ID NO: 66.

9. The isolated antibody of any one of claims 1 to 4, wherein said antibody has a light chain kappa chain constant region encoded by the polynucleotide as shown in
10 SEQ ID NO: 67.

10. An isolated nucleic acid, comprising a polynucleotide encoding the antibody of any one of claims 1 through 9.

15 11. An expression vector comprising a nucleic acid according to claim 10.

12. A host cell stably transfected with the expression vector of claim 11, wherein the host cell expresses a protein of any one of claims 1 through 9.

20 13. The host cell of claim 12, wherein the host cell is a Chinese Hamster Ovary cell, SP2/0 myeloma cell, NS0 myeloma cell, a Syrian hamster ovary cell, or an embryonic kidney cell.

14. A process for producing an antibody, comprising cultivating the host cell
25 of claim 12 or 13 and recovering the polypeptide encoded by said polynucleotide from the culture.

15. A pharmaceutical composition comprising the antibody of any one of claims 1 through 9 and one or more pharmaceutically acceptable carrier, excipient or
30 diluent.

- 43 -

16. A pharmaceutical composition comprising the antibody of any one of claims 1 through 9, when said antibody is produced according to the process of claim 14, and one or more pharmaceutically acceptable carrier, excipient or diluents.

5 17. An antibody according to any one of claims 1 to 9 for use in the treatment of rheumatoid arthritis or osteoarthritis.

18. A pharmaceutical composition according to any one of claim 15 or 16 for use in the treatment of rheumatoid arthritis or osteoarthritis.